WO1997020561A1 - Composition for treating pain - Google Patents

Composition for treating pain Download PDF

Info

Publication number
WO1997020561A1
WO1997020561A1 PCT/US1996/019309 US9619309W WO9720561A1 WO 1997020561 A1 WO1997020561 A1 WO 1997020561A1 US 9619309 W US9619309 W US 9619309W WO 9720561 A1 WO9720561 A1 WO 9720561A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
alkyl
alkoxy
substituted
group
Prior art date
Application number
PCT/US1996/019309
Other languages
French (fr)
Inventor
Charles H. Mitch
Harlan E. Shannon
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Priority to HU9902118A priority Critical patent/HUP9902118A2/en
Priority to EA199800533A priority patent/EA199800533A1/en
Priority to IL12441996A priority patent/IL124419A0/en
Priority to AU12791/97A priority patent/AU705031B2/en
Priority to NZ324988A priority patent/NZ324988A/en
Priority to KR1019980704267A priority patent/KR19990071976A/en
Priority to PL96327137A priority patent/PL327137A1/en
Priority to JP9521397A priority patent/JP2000501709A/en
Priority to EP96943584A priority patent/EP0871445A4/en
Publication of WO1997020561A1 publication Critical patent/WO1997020561A1/en
Priority to NO982562A priority patent/NO982562L/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a method for using a combination of compounds for treating pain.
  • This invention relates to a therapeutic combination of compounds to provide analgesic activity.
  • More active analgesic combinations effects are in constant demand because they offer the attractive possibility of relieving pain with reduced dosages, thereby diminishing the expected side effects and toxicity that would otherwise result from higher dosages. It would be particularly desirable to acquire a synergistic combination effect.
  • Such a composition is the subject of the present invention.
  • composition of this invention provides a surprising synergistically effective treatment for pain using compounds which are independently known in the art.
  • the synergistic effect of the present composition provides a means for treating pain using a lower dosage of each compound in the composition, thus providing a treatment with a more desirable side effect profile.
  • the present invention provides a composition useful for the treatment of pain, comprising a compound selected from the group consisting of:
  • R 1 is hydrogen, Ci-C ⁇ alkyl or phenyl-C ⁇ -C 4 alkyl, in which the phenyl group may be substituted with halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy;
  • R 2 is Ci-C ⁇ alkyl, C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, branched or unbranched with 1-6 carbon atoms inclusive, which group may be optionally substituted with fluoro, hydroxy or phenyl optionally substituted with fluoro, trifluoromethyl, lower alkyl, hydroxy, or lower alkoxy;
  • R 3 and R 4 are independently hydrogen, C1-C 6 alkyl, C 3 -C 6 cycloalkyl, phenyl optionally substituted with halogen trifluroromethyl, C1-C 4 alkyl, hydroxy, or C 1 -C 4 alkoxy, or phenyl-C ⁇ -C 4 alkyl, in which the phenyl group may be substituted with halogen, C 1 -C 4 alkyl or C1-C 4 alkoxy;
  • R 6 at any position on the benzene ring represents linear, branched or cyclic Ci-C ⁇ alkyl, C 2 -C8 alkenyl or C 2 - C 8 alkynyl or the radical
  • R 7 and R 8 which may be identical or different represent hydrogen, linear C 3. -C 8 alkyl, C 2 -C8 alkenyl or C 2 - C ⁇ alkynyl or form together with the nitrogen atom to which they are attached a carbonaceous hetercyclic radical optionally containing another heteroatom, or the radical OR 9 ,
  • R 9 representing hydrogen, linear, branched or cyclic Ci-C ⁇ alkyl, C 2 -C 8 alkenyl or C 2 -C 8 alkynyl or aryl containing up to 14 carbon atoms, or the radical SR 10 or S(0)R 1:L , R 10 and
  • R 11 represent linear, branched or cyclic Ci-C ⁇ alkyl, C 2 -C 8 alkenyl or C 2 -C 8 alkynyl, or R 5 represents naphthyl optionally substituted with R 6 ' ' R 6 ' being defined above for R 6 ;
  • R 13 at any position on the benzene ring represents linear, branched or cyclic Ci-Cs alkyl, C 2 -C 8 alkenyl or C 2 - C 8 alkynyl or the radical
  • R 14 and R 15 which may be identical or different represent hydrogen, linear C ⁇ -C 8 alkyl, 2 -C 8 alkenyl or C 2 - C ⁇ alkynyl or form together with the nitrogen atom to which they are attached a carbonaceous hetercyclic radical optionally containing another heteroatom, or the radical or O 2 , or OR 12 ', R 12 ' representing hydrogen, linear, branched or cyclic Ci-C ⁇ alkyl, C 2 -C 8 alkenyl or C 2 -C 8 alkynyl or aryl containing up to 14 carbon atoms, or the radical SR 16 or S(0)R 17 , R 16 and R 17 represent linear, branched or cyclic C ⁇ _- C8 alkyl, C 2 -C 8 alkenyl or C 2 -Cg alkynyl, or R 12 represents naphthyl optionally substituted with R 13 ' - R 13 ' being defined above for R 13 ;
  • R 18 , R 19 , and R 20 represents nitrogen and the remainder represent carbon atoms; substituted on one of the ring carbon atoms with a R 24 substituent represented by a non ⁇ aromatic azacyclic or azabicyclic ring system and independently substituted on each of the other ring carbon atoms with R 23 , R 21 , or R 22 substituent of low lipophilicity or a hydrocarbon having a maximum of 20 carbon atoms;
  • R 28 , R 29 or R 30 is an oxygen atom and the other two are nitrogen atoms, and the dotted circle represents aromaticity (two double bonds) thus forming a 1, 3, 4-oxadiazole or 1, 2, 4-oxadiazole nucleus
  • R 31 represents a non-aromatic '927azacycle or ' 927azabicyclic ring system
  • R 32 represents a substituent which is convertable in vivo to an amino group
  • R 34 represents a non-aromatic; non-fused 1- azabicyclic ring system
  • R 35 , R 36 , and R 37 independently represent hydrogen, F, Cl, Br, -CF 3 , -OR 38 , - R 38 R 39 , -NHOR 38 , - HNH 2 , -CN, COR 40 , or a substituted or unsubstituted, saturated or unsaturated hydrocarbon group, provided that at least one of R 35 , R 36 , and R 37 is other than hydrogen or a hydrocarbon group, or R 35 and R 36 or R 37 taken together form a C ⁇ _ 6 alkylenedioxy ring, wherein R 38 is Ci- ⁇ alkyl, C 2 - 6 alkenyl or C 2 - 6 alkynyl, R 39 is hydrogen, C ⁇ _g alkyl,or -COCH 3 , and R 40 represents OH, -OR 38 , NHR 39 , or -NR 38 R 39
  • R 43 is alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to six carbon atoms, alkenyl of from two to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to six carbon atoms, alkynyl of from two to six carbon atoms, substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms,
  • R 47 and R 48 are independently hydrogen, fluorine, chlorine, bromine, hydroxy, alkyl of from one to three carbon atoms, or alkoxy of from one to three carbon atoms, or alkoxy of from one to four carbon atoms, or
  • R 47 and R 48 are as defined above; X is oxygen or sulfur;
  • R 44 is alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms alkenyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or
  • R45 and R46 are each independently hydrogen, alkyl of from one to twenty carbon atoms, alkyl of from one to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to twenty carbon atoms, alkenyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to twenty carbon atoms, alkynyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to eight carbon atoms, phenyl, phenyl substituted with alkyl of from one to four carbon atoms, alkyl of from one to four carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkoxy of from one to four carbon atoms, chlorine, bromine, hydroxy,
  • R 49 is hydrogen, alkyl of from one to ten carbon atoms, alkyl of from one to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to ten carbon atoms, alkenyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms and n is as defined above,
  • R 50 is hydrogen or alkyl of from one to six carbon atoms
  • R 51 is selected from the group consisting of
  • R 52 is hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms or aryl; n' is zero or an integer of one or two; X' is carbon or nitrogen; and ... represents a single or double bond with the proviso that when, ____ represents a double bond X 1 is nitrogen and when _____ represents a single bond X' is CH2;
  • R 53 is selected from the group consisting of
  • R54, R55, R56, and R57 are each independenty hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms, phenyl or phenyl substituted by one to four substituents selected from C1-C10 alkyl, alkoxy, C1-C10 halogen or trifluoromethyl; n 1 is an interger of one or two;
  • X is oxygen, sulfur, or -N-R ⁇ 2 , wherein R 62 is hydrogen or alkyl of from one to ten carbon atoms; R 58 is selected from the group consisting of
  • R 59 , R 60 , and R 61 are each independently hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms or aryl; represents a single or double bond with the proviso that when represents a double bond R 57 and R 60 are absent;
  • R 63 , R 64 , and R 65 are each independently hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms, phenyl or phenyl substituted by one to four substituents selected from the group consisting of alkyl, alkoxy, thioalkoxy, halogen, and trifluoromethyl;
  • R 66 is hydrogen, hydroxy or alkoxy of from one to ten carbon atoms; and
  • R 67 is selected from the group consisting of
  • R 69 is hydrogen and R 67 is hydrogen, alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms, alkenyl of from three to six carbon atoms, substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or
  • R 68 and R 69 are taken together with the nitrogen atom to which they are attached to form a ring denoted by
  • R 73 is hydrogen, alkyl of from one to ten carbon atoms, alkyl of from one to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to ten carbon atoms, alkenyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to ten carbon atoms or alkynyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms;
  • R 70 is hydrogen, alkyl of from one to six carbon atoms, alkyl of form one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms, alkenyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three
  • n is an integer from one to three and R68 are as defined above;
  • R 71 and R 72 are each independently hydrogen, alkyl of from one to twenty carbon atoms, alkyl of from one to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to twenty carbon atoms, alkenyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to twenty carbon atoms, alkynyl of from three to twenty carbon atoms substituted with dydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to eight carbon atoms, phenyl, phenyl substituted with alkyl of from one to four carbon atoms, alkyl of from one to four carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkoxy of from one to four carbon atoms, chlorine, bromine, hydroxy, nitro or trifluoromethyl
  • n' and R 73 are ad defined above,
  • R 74 is hydrogen or alkyl of from one to six carbon atoms
  • Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, or three nitrogen atoms, any amino nitrogen being substituted by a C ⁇ - 2 alkyl, cyclopropyl or propargyl group, and any ring carbon atom being optionally substituted by a group R x ; or a group
  • Ri, R 2 and R3 are independently selected from hydrogen, halogen, CN, OR 4 , SR 4 , N(R. ⁇ ) 2 , NHCOR 4 , NHCOOCH 3 , NHCOOC 2 H 5 , NHOR 4 , NHNH , N0 2 , COR 4 , COR1 3 , cyclopropyl, C2- 5 straight chain alkenyl, C 2 - 5 straight chain alkynyl or C 1 - 5 straight chain alkyl optionally terminally substituted with OR4, (R )2» SR4, CO2R4, CON(R4)2 or one, two or three halogen atoms, in which each
  • Q' represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises two or three nitrogen atoms, any amino nitrogen being substituted by a Cl-2 alkyl, cyclopropyl or propargyl group
  • r represents the integer of 2 or 3
  • represents an integer of 1 or 2
  • t represents 0, with the proviso that when Y is hydrogen s is 1;
  • R 75 represents in which each of p and q independently represents an integer of 2 to 4, r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;
  • R 76 is a group OR 78 , where R 78 is C ⁇ _4 alkenyl, C 2 - 4 alkynyl, a group OCOR 79 where R 79 is hydrogen or R 78 , or a group NHR 80 or NR 81 , R 82 , where R 80 , R 81 and R 82 are independently C 1 - 2 alkyl; and R 77 is hydrogen or C ⁇ _ 4 alkyl, subject to the proviso that when R 76 is a group OCOR 79 or a group NHR 80 , R 77 is alkyl;
  • Compound to Synergistic Analgesic of from about 1 to about
  • the present invention provides a method for treating pain comprising administering to a patient in need thereof, an anagesic composition comprising a compound selected from the group consisting of:
  • R 1 is hydrogen, C ⁇ -C 6 alkyl or phenyl-C ⁇ -C 4 alkyl, in which the phenyl group may be substituted with halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy;
  • R 2 is Ci-Cgalkyl, C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, branched or unbranched with 1-6 carbon atoms inclusive, which group may be optionally substituted with fluoro, hydroxy or phenyl optionally substituted with fluoro, trifluoromethyl, lower alkyl, hydroxy, or lower alkoxy;
  • R 3 and R 4 are independently hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, phenyl optionally substituted with halogen trifluroromethyl, C 1 -C 4 alkyl, hydroxy, or C 1 -C 4 alkoxy, or phenyl-C ⁇ -C 4 alkyl, in which the phenyl group may be substituted with halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy;
  • R 6 at any position on the benzene ring represents linear, branched or cyclic Ci-Cs alkyl, C 2 -C 8 alkenyl or C2- CQ alkynyl or the radical N ⁇
  • R 7 and R 8 which may be identical or different represent hydrogen, linear Ci-Cs alkyl, C 2 -C 8 alkenyl or C 2 - C ⁇ alkynyl or form together with the nitrogen atom to which they are attached a carbonaceous hetercyclic radical optionally containing another heteroatom, or the radical OR 9 , R 9 representing hydrogen, linear, branched or cyclic Ci-C ⁇ alkyl, C 2 -C 8 alkenyl or C 2 -C 8 alkynyl or aryl containing up tc 14 carbon atoms, or the radical SR 10 or S ⁇ 0)R 1:L , R 10 and R 11 represent linear, branched or cyclic Ci-C ⁇ alkyl, C 2 -C 8 alkenyl or C 2 -C 8 alkynyl, or R 5 represents naphthyl optionally substituted with R 6 ' ⁇ R 6 ' being defined above for R 6 ;
  • R 13 at any position on the benzene ring represents linear, branched or cyclic Ci-C ⁇ alkyl, C2-C8 alkenyl or C 2 - C ⁇ alkynyl or the radical
  • R 14 and R 15 which may be identical or different represent hydrogen, linear C -C ⁇ alkyl, C 2 -C 8 alkenyl or C 2 ' Cs alkynyl or form together with the nitrogen atom to which they are attached a carbonaceous hetercyclic radical optionally containing another heteroatom, or the radical or NO 2 , or OR 12 ', R 12 ' representing hydrogen, linear, branched or cyclic Ci-Ce alkyl, C 2 -C 8 alkenyl or C 2 -C 8 alkynyl or aryl containing up to 14 carbon atoms, or the radical SR 16 or S(0)R 17 , R 16 and R 17 represent linear, branched or cyclic C ⁇ C ⁇ alkyl, C 2 -C 8 alkenyl or C 2 -C 8 alkynyl, or R 12 represents naphthyl optionally substituted with R 13 ' ' R 13 ' being defined above for R 13 ;
  • R 18 , R 19 , and R 20 represents nitrogen and the remainder represent carbon atoms; substituted on one of the ring carbon atoms with a R 24 substituent represented by a non ⁇ aromatic azacyclic or azabicyclic ring system and independently substituted on each of the other ring carbon atoms with R 23 , R 21 , or R 22 substituent of low lipophilicity or a hydrocarbon having a maximum of 20 carbon atoms;
  • R 28 , R 29 or R 30 is an oxygen atom and the other two are nitrogen atoms, and the dotted circle represents aromaticity (two double bonds) thus forming a
  • R 31 represents a non-aromatic '927azacycle or ' 927azabicyclic ring system
  • R ;i2 represents a substituent which is convertable in vivo to an amino group
  • R 34 represents a non-aromatic; non-fused 1- azabicyclic ring system
  • R 35 , R 36 , and R 37 independently represent hydrogen, F, Cl, Br, -CF 3 , -OR 38 , -NR 38 R 39 , -NHOR 38 , -NHNH , -CN, COR 40 , or a substituted or unsubstituted, saturated or unsaturated hydrocarbon group, provided that at least one of R 35 , R 36 , and R 37 is other than hydrogen or a hydrocarbon group, or R 35 and R 35 or R 37 taken together form a Ci-galkylenedioxy ring, wherein R 38 is C ⁇ _ 6 alkyl, C 2 ⁇ 6 alkenyl or C 2 - 6 alkynyl, R 39 is hydrogen, C ⁇ - 6 alkyl,or -COCH 3 , and R 40 represents OH, -OR 38 , NHR 39 , or -NR 38 R 39
  • R 43 is alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to six carbon atoms, alkenyl of from two to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to six carbon atoms, alkynyl of from two to six carbon atoms, substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms,
  • R 47 and R 48 are independently hydrogen, fluorine, chlorine, bromine, hydroxy, alkyl of from one to three carbon atoms, or alkoxy of from one to three carbon atoms, or alkoxy of from one to four carbon atoms, or
  • R 47 and R 48 are as defined above;
  • X is oxygen or sulfur
  • R 44 is alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms alkenyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or
  • R45 and R46 are each independently hydrogen, alkyl of from one to twenty carbon atoms, alkyl of from one to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to twenty carbon atoms, alkenyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to twenty carbon atoms, alkynyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to eight carbon atoms, phenyl, phenyl substituted with alkyl of from one to four carbon atoms, alkyl of from one to four carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkoxy of from one to four carbon atoms, chlorine, bromine, hydroxy,
  • R 49 is hydrogen, alkyl of from one to ten carbon atoms, alkyl of from one to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to ten carbon atoms, alkenyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms and n is as defined above,
  • R 50 is hydrogen or alkyl of from one to six carbon atoms
  • R 51 is selected from the group consisting of
  • R 52 is hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms or aryl; n' is zero or an integer of one or two; X' is carbon or nitrogen; and ... represents a single or double bond with the proviso that when, _____ represents a double bond X' is nitrogen and when .. t represents a single bond X' is CH 2 ;
  • R 53 is selected from the group consisting of
  • R54, R55, R56, and R57 are each independenty hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms, phenyl or phenyl substituted by one to four substituents selected from C1-C10 alkyl, alkoxy, C1-C10 halogen or trifluoromethyl; n' is an interger of one or two;
  • X is oxygen, sulfur, or -N-R 62 , wherein R 62 is hydrogen or alkyl of from one to ten carbon atoms; R 58 is selected from the group consisting of
  • R 59 , R 60 , and R 61 are each independently hydrogen, alkyl of froti one to ten carbon atoms, alkynyl of from two to ten carbon atoms or aryl; represents a single or double bond witn the proviso that when represents a double bond R 57 and R 60 are absent;
  • R 63 , R 64 , and R 65 are each independently hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms, phenyl or phenyl substituted by one to four substituents selected from the group consisting of alkyl, alkoxy, thioalkoxy, halogen, and trifluoromethyl;
  • R 66 is hydrogen, hydroxy or alkoxy of from one to ten carbon atoms; and
  • R G7 is selected from the group consisting of
  • R 69 is hydrogen and R 67 is hydrogen, alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms, alkenyl of from three to six carbon atoms, substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or
  • R 6i3 and R 69 are taken together with the nitrogen atom to which they are attached to form a ring denoted by
  • R 73 is hydrogen, alkyl of from one to ten carbon atoms, alkyl of from one to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to ten carbon atoms, alkenyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to ten carbon atoms or alkynyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms;
  • R 70 is hydrogen, alkyl of from one to six carbon atoms, alkyl of form one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms, alkenyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three
  • n is an integer from one to three and R68 are as defined above;
  • R 71 and R 72 are each independently hydrogen, alkyl of from one to twenty carbon atoms, alkyl of from one to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to twenty carbon atoms, alkenyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to twenty carbon atoms, alkynyl of from three to twenty carbon atoms substituted with dydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to eight carbon atoms, phenyl, phenyl substituted with alkyl of from one to four carbon atoms, alkyl of from one to four carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkoxy of from one to four carbon atoms, chlorine, bromine, hydroxy, nitro or trifluoromethyl
  • n" and R 73 are ad defined above,
  • R 74 is hydrogen or alkyl of from one to six carbon atoms.
  • Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, or three nitrogen atoms, any amino nitrogen being substituted by a C ⁇ - 2 alkyl, cyclopropyl or propargyl group, and any ring carbon atom being optionally substituted by a group Ri; or a group
  • R 2 and R 3 are independently selected from hydrogen, halogen, CN, OR4, SR 4 , (R4) 2 » NHCOR 4 , NHCOOCH 3 , NHCOOC 2 H 5 , NHOR 4 , NHNH 2 , NO 2 , COR 4 , COR5, cyclopropyl, C 2 - 5 straight chain alkenyl, C 2 - 5 straight chain alkynyl or C 1 - 5 straight chain alkyl optionally terminally substituted with OR4, N(R )2/ SR4, CO2R4, CON(R4)2 or one, two or three halogen atoms, in which each R4 is independently hydrogen or C
  • Q' represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises two or three nitrogen atoms, any amino nitrogen being substituted by a Cl-2 alkyl, cyclopropyl or propargyl group
  • r represents the integer of 2 or 3
  • s represents an integer of 1 or 2
  • t represents 0, with the proviso that when Y is hydrogen s is 1;
  • R 75 represents in which each of p and q independently represents an integer of 2 to 4, r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;
  • R 76 is a group OR 78 , where R 78 is C1- 4 alkenyl, C 2 - 4 alkynyl, a group OCOR 79 where R 79 is hydrogen or R 78 , or a group NHR 80 or NR 81 , R 82 , where R 80 , R 81 and R 82 are independently C 1 - 2 alkyl; and R 77 is hydrogen or C ⁇ - 4 alkyl, subject to the proviso that when R 76 is a group OCOR 79 or a group NHR 80 , R 77 is alkyl;
  • Compound to Synergistic Analgesic of from about 1 to about
  • Synergistic Analgesic and “Synergistic Analgesics” refer to the group consisting of Nonsteroidal anti-inflammatory drugs (NSAIDS) , acetaminophen, alpha-adrenergic compounds, and opioids.
  • Selected Muscarinic As used herein, the term "Selected Muscarinic
  • Compound and “Selected Muscarinic Compounds” refers to a compound selected from the group consisting of
  • R 1 is hydrogen, C -C ⁇ alkyl or phenyl-C ⁇ -C 4 alkyl, in which the phenyl group may be substituted with halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy;
  • R 2 is C -Cgalkyl, C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, branched or unbranched with 1-6 carbon atoms inclusive, which group may be optionally substituted with fluoro, hydroxy or phenyl optionally substituted with fluoro, trifluoromethyl, lower alkyl, hydroxy, or lower alkoxy;
  • R 3 and R 4 are independently hydrogen, Ci-C ⁇ alkyl, C 3 -C 6 cycloalkyl, phenyl optionally substituted with halogen trifluroromethyl, C 1 -C 4 alkyl, hydroxy, or C -C 4 alkoxy, or phenyl-C ⁇ C 4 alkyl, in which the phenyl group may be substituted with halogen, C 1 -C 4 alkyl or C -C 4 alkoxy; ⁇ 37 -
  • R 6 at any position on the benzene ring represents linear, branched or cyclic Ci-Cs alkyl, C 2 -C 8 alkenyl or C 2 - C ⁇ alkynyl or the radical
  • R 7 and R 8 which may be identical or different represent hydrogen, linear Ci-C ⁇ alkyl, C 2 -C8 alkenyl or C 2 - C ⁇ alkynyl or form together with the nitrogen atom to which they are attached a carbonaceous hetercyclic radical optionally containing another heteroatom, or the radical OR 9 , R 9 representing hydrogen, linear, branched or cyclic C ⁇ C ⁇ alkyl, C 2 ⁇ Ce alkenyl or C 2 ⁇ C ⁇ alkynyl or aryl containing up to 14 carbon atoms, or the radical SR 10 or S(0)R 1] -, R 10 and R 11 represent linear, branched or cyclic Ci-Cs alkyl, C 2 ⁇ C ⁇ alkenyl or C 2 ⁇ C ⁇ alkynyl, or R 5 represents naphthyl optionally substituted with R 6 '- R 6 ' being defined above for R 6 ;
  • R 13 at any position on the benzene ring represents linear, branched or cyclic Ci-Cs alkyl, C 2 ⁇ C ⁇ alkenyl or C 2 - CQ alkynyl or the radical
  • R 14 and R 15 which may be identical or different represent hydrogen, linear C -C ⁇ alkyl, C 2 -C ⁇ alkenyl or C 2 - C ⁇ alkynyl or form together with the nitrogen atom to which they are attached a carbonaceous hetercyclic radical optionally containing another heteroatom, or the radical or O , or OR 12 ', R 12 ' representing hydrogen, linear, branched or cyclic Ci-Cs alkyl, C 2 ⁇ Ce alkenyl or C 2 -C 8 alkynyl or aryl containing up to 14 carbon atoms, or the radical SR 16 or S(0)R 17 , R 16 and R 17 represent linear, branched or cyclic C ⁇ C ⁇ alkyl, C 2 ⁇ C ⁇ alkenyl or C 2 -C 8 alkynyl, or R 12 represents naphthyl optionally substituted with R 13 ' - R 13 ' being defined above for R 13 ;
  • R 18 , R 19 , and R 20 represents nitrogen and the remainder represent carbon atoms; substituted on one of the ring carbon atoms with a R 24 substituent represented by a non ⁇ aromatic azacyclic or azabicyclic ring system and independently substituted on each of the other ring carbon atoms with R 23 , R 21 , or R 22 substituent of low lipophilicity or a hydrocarbon having a maximum of 20 carbon atoms;
  • R 28 , R 29 or R 30 is an oxygen atom and the other two are nitrogen atoms, and the dotted circle represents aromaticity (two double bonds) thus forming a 1,3, 4-oxadiazole or 1, 2, 4-oxadiazole nucleus
  • R 31 represents a non-aromatic ' 927azacycle or ' 27azabicyclic ring system
  • R 32 represents a substituent which is convertable in vivo to an amino group
  • R 34 represents a non-aromatic; non-fused 1- azabicyclic ring system
  • R 35 , R 36 , and R 37 independently represent hydrogen, F, Cl, Br, -CF 3 , -OR 38 , -NR 38 R 39 , -NHOR 38 , -NHNH 2 , -CN, COR 40 , or a substituted or unsubstituted, saturated or unsaturated hydrocarbon group, provided that at least one of R 35 , R 36 , and R 37 is other than hydrogen or a hydrocarbon group, or R 35 and R 36 or R 37 taken together form a C ⁇ - 6 alkylenedioxy ring, wherein R 38 is Ci- ⁇ alkyl, C 2 - 6 lkenyl or C 2 - 6 lkynyl, R 39 is hydrogen, C _ 6 alkyl,or -COCH 3 , and R 40 represents OH, -OR 38 , NHR 39 , or -NR 38 R 39 X
  • R 43 is alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to six carbon atoms, alkenyl of from two to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to six carbon atoms, alkynyl of from two to six carbon atoms, substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms,
  • n is zero or an integer of one to eight and R 47 and R 4 ⁇ are independently hydrogen, fluorine, chlorine, bromine, hydroxy, alkyl of from one to three carbon atoms, or alkoxy of from one to three carbon atoms, or alkoxy of from one to four carbon atoms, or
  • R 47 and R 48 are as defined above;
  • X is oxygen or sulfur;
  • R 44 is alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms alkenyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or
  • R45 and R46 are each independently hydrogen, alkyl of from one to twenty carbon atoms, alkyl of from one to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to twenty carbon atoms, alkenyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to twenty carbon atoms, alkynyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to eight carbon atoms, phenyl, phenyl substituted with alkyl of from one to four carbon atoms, alkyl of from one to four carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkoxy of from one to four carbon atoms, chlorine, bromine, hydroxy,
  • R 49 is hydrogen, alkyl of from one to ten carbon atoms, alkyl of from one to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to ten carbon atoms, alkenyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms and n is as defined above,
  • R 50 is hydrogen or alkyl of from one to six carbon atoms
  • R 51 is selected from the group consisting of
  • R 52 is hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms or aryl; n' is zero or an integer of one or two; X' is carbon or nitrogen; and ... represents a single or double bond with the proviso that when, ________ represents a double bond X' is nitrogen and when
  • _______ represents a single bond X' is CH2;
  • R 53 is selected from the group consisting of
  • R54, R55, R56, and R57 are each independenty hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms, phenyl or phenyl substituted by one to four substituents selected from C1-C10 alkyl, alkoxy, C1-C10 halogen or trifluoromethyl; n' is an interger of one or two;
  • X is oxygen, sulfur, or -N-R 62 , wherein R 62 is hydrogen or alkyl of from one to ten carbon atoms; R 58 is selected from the group consisting of
  • R 5 ', R 60 , and R 61 are each independently hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms or aryl; represents a single or double bond with the proviso that when represents a double bond R 57 and R 60 are absent;
  • R 63 , R 64 , and R 65 are each independently hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms, phenyl or phenyl substituted by one to four substituents selected from the group consisting of alkyl, alkoxy, thioalkoxy, halogen, and trifluoromethyl;
  • R 66 is hydrogen, hydroxy or alkoxy of from one to ten carbon atoms; and
  • R 67 is selected from the group consisting of
  • R 69 is hydrogen and R 67 is hydrogen, alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms, alkenyl of from three to six carbon atoms, substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or
  • R 6a and R 69 are taken together with the nitrogen atom to which they are attached to form a ring denoted by
  • R 73 is hydrogen, alkyl of from one to ten carbon atoms, alkyl of from one to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to ten carbon atoms, alkenyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to ten carbon atoms or alkynyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms;
  • R 70 is hydrogen, alkyl of from one to six carbon atoms, alkyl of form one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms, alkenyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three
  • n is an integer from one to three and R68 are as defined above;
  • R 71 and R 72 are each independently hydrogen, alkyl of from one to twenty carbon atoms, alkyl of from one to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to twenty carbon atoms, alkenyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to twenty carbon atoms, alkynyl of from three to twenty carbon atoms substituted with dydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to eight carbon atoms, phenyl, phenyl substituted with alkyl of from one to four carbon atoms, alkyl of from one to four carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkoxy of from one to four carbon atoms, chlorine, bromine, hydroxy, nitro or trifluoromethyl
  • n' and R 73 are ad defined above,
  • R 74 is hydrogen or alkyl of from one to six carbon atoms.
  • Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, or three nitrogen atoms, any amino nitrogen being substituted by a C ⁇ - 2 alkyl, cyclopropyl or propargyl group, and any ring carbon atom being optionally substituted by a group Ri; or a group
  • Ri, R 2 and R 3 are independently selected from hydrogen, halogen, CN, OR 4 , SR 4 , N(R ) 2 , NHCOR 4 , NHCOOCH 3 , NHCOOC 2 H 5 , NHOR 4 , NHNH 2 , N0 2 , COR 4 ,
  • R6 is a group OR8 where R8 is C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, a group OCOR9 where R9 is hydrogen or R8, or a group NHR10 or NRHR12 where R ⁇ o, Rll and R12 are independently Ci- 2 alkyl and R7 is hydrogen or C1-4 alkyl, subject to the proviso that when R ⁇ is a group OCOR9 or NHR ⁇ o , 7 is C1-4 alkyl
  • Q' represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises two or three nitrogen atoms, any amino nitrogen being substituted by a Cl-2 alkyl, cyclopropyl or propargyl group
  • r represents the integer of 2 or 3
  • s represents an integer of 1 or 2
  • t represents 0, with the proviso that when Y is hydrogen s is 1;
  • R 75 represents in which each of p and q independently represents an integer of 2 to 4, r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;
  • R 76 is a group OR 78 , where R 78 is C ⁇ _ 4 alkenyl, C 2 - 4 alkynyl, a group OCOR 79 where R 79 is hydrogen or R 78 , or a group NHR 80 or NR 81 , R 82 , where R 80 , R 81 and R 82 are independently C 1 - 2 alkyl; and R 77 is hydrogen or C ⁇ -4alkyl, subject to the proviso that when R 76 is a group OCOR 79 or a group NHR 80 , R 77 is alkyl;
  • low lipophilicity refers to hydrogen, halogen, -CF 3 , -OR 25 , -NR 25 R 26 ' " NHOR 25 - -NHNH 2 , -CN, COR 8 , or a substituted or unsubstituted, saturated or unsaturated hydrocarbon group; wherein R 25 is hydrogen, Ci-C ⁇ alkyl, C 2 - 6 alkenyl or C 2 - 6 alkynyl; R 26 is hydrogen, alkyl or -COCH 3 , and R27 represents -OR 25 or -NR 25 R 26 - '
  • azacyclic or azabicyclic ring system is a non-aromatic ring system containing one nitrogen atom as the sole heteroatom.
  • the ring system contains from 4-10 ring atoms, preferably from 5-8 ring atoms.
  • the ring system contains a tertiary amino nitrogen atom in a ce.ged structure.
  • the bicyclic systems may be fused, spiro, or birdged.
  • the nitrogen atom is at a bridgehead in a bicyclic system. Examples of such heteroatoms include the heteroatoms described in U.S. Patent 5,260,293, columns 2-3, which has been incorporated by reference.
  • '927 azacyclic or '927 azabicyclic refers to a non-aromatic ring system containing one nitrogen atom as the sole heteroatom.
  • the ring contains from 4 to 10 ring atoms.
  • the bicyclic systems may be fused, spiro or bridged. Examples of such heteroatoms include the bicyclic heteroatoms described in U.S. Patent 5,242,927 column 2, which has been incorporated by reference.
  • the most preferred ' 927azabicyclic or ' 927azacyclic systems include pyrrolidine, 1, 2, 5, 6- etrahydropyridine, quinuclidine or 1- azabicyclo[2.2.l]heptane ring, optionally substituted with me-hyl or hydroxy.
  • An especially preferred '927 azabicyclic ring is quinuclidine, which is substituted by hydrogen, methyl or hydroxy at any available atom.
  • Groups which are converted in vivo to an amino group on the compounds claimed herein for treating pain may be ascertained by administering the compound to a human or an animal and detecting, by conventional analytical techniques, the presence of the corresponding compound having an amino substituent in the urine of a human or animal.
  • groups which are hydrolysable in vivo to an amino group such as amido, urethan substituents.
  • hydrocarbon group includes groups having up to 20 carbon atoms, suitably up to 10, and conveniently up to 8 carbon atoms.
  • Suitable hydrocarbon groups include C ⁇ _ 8 alkyl, C 2 - ⁇ alkenyl, C 2 - ⁇ alkynyl, C 3 _7cycloalkyl, C 3 _7cycloalkylC ⁇ _ 6 alkyl, aryl and arylCi-galkyl.
  • Suitable R 34 groups include the following:
  • R 41 and R 42 may be present at any position, including the point of attachment to the benzene ring, and independently represent hydrogen, C ⁇ _ 4 alkyl, F, Br, Cl, C 1 - 4 alkoxy, hydroxy, carboxy, or C ⁇ - 4 alkyoxycarbonyl or R 41 and R 42 together represent cabonyl.
  • the nitrogen atom may be substituted by hydrogen or C 1 - 4 alkyl.
  • phenyl-C ⁇ -C 4 alkyl designates an alkyl group which is substituted with a phenyl group.
  • Preferred phenyl-alkyl groups include benzyl, 1- and 2-phenylethyl, 1-, 2-, 3-phenyla propyl and 1-methyl-1-phenylethyl .
  • the phenyl group may be optionally be substituted with from 1-3 independently selected named substituents.
  • heterocyclic radical means that a heterocyclic radical optionally containing another heteroatom, for example, S or 0.
  • groups include, but are not limited to, piperidyl, piperazynyl, morpholinyl, and pyrrolidinyl.
  • alkyl refers to the number of carbon atoms indicated; however, when no number is specified, the term refers to C 1 - 6 alkyl.
  • the alkyl may be linear or branched unless specified.
  • halogen refers to chloro, bromo, and fluoro substituents.
  • alkynyl has its accepted meaning; however, if the number of carbon atoms are unspecified, it refers to C 2 - 10 alkynyl.
  • the alkynyl group may be linear or branched unless specified.
  • alkoxy refers to C ⁇ _ 4 alkoxy unless specified.
  • analgesic dose represents an amount of compound necessary to prevent or treat a human susceptible to or suffering from pain following administration to such human.
  • the active compounds are effective over a wide dosage range. For example, dosages per day will normally fall within the range of about 0.005 to about 500 mg/kg of body weight. In the treatment of adult humans, the range of about 0.05 to about 100 mg/kg, in single or divided doses, is preferred.
  • the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way.
  • the present compounds are preferably administered orally to humans susceptible to or suffering from anxiety, the compounds may also be administered by a variety of other routes such as the transdermal, parenterally, subcutaneous, intranasal, intramuscular and intravenous routes.
  • Such formulations may be designed to provide delayed or controlled release using formulation techniques which are known in the art.
  • NSAIDS represents a nonsteroidal anti-inflammatory drug which can be identified as such by the skilled artisan.
  • the Merck Manual, 16th Edition, Merck Research Laboratories (1990) pp 1308 - 1309 provide well known examples of NSAIDS.
  • the term is intended to include, but is not limited to salicylates such as aspirin, indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac.
  • NSAIDS include aspirin, ibuprofen, and naproxen.
  • NSAIDS are indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac.
  • NSAIDS include aspirin and ibuprofen.
  • the salicylates may include acetylsalicylic acid, sodium acetylsalicylic acid, calcium acetylsalicylic acid, salicylic acid, and sodium salicylate.
  • An especially preferred NSAID is ibuprofen.
  • acetaminophen shall have the art accepted meaning and refers to N-(4- Hydroxyphenyl)acetamide and 4 ' -hydroxyacetanilide.
  • the compound is claimed in U.S. Patent No. 2,998,450 and is known to the skilled artisan.
  • central alpha-adrenergic active compounds represents a compound having central alpha-adrenergic receptor activity.
  • the most preferred central alpha-adrenergic active compound is clonidine or a pharmaceutically acceptable salt thereof having the chemical name: 2- (2, 6-dichlorophenylamino) -2- imidazoline.
  • Clonidine is known to be useful for treating hypertension. see Physicians' Desk Reference, 45th Ed. (1991) p. 673.
  • opioid represents opioid analgesics and antagonists including natural opioid analgesics, synthetic opioid analgesics, opioid antagonists and opioid agonist-antagonists.
  • Preferred an opioid compounds are selected from the group consisting of morphine, codeine, meperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, brompton's cocktail, naloxone, naltrexone, pentazocine, butorphanol, nabuphine, and buprenorphine. More preferred opioid compounds are selected from the group consisting of codeine, nabuphine, naloxone, and naltrexone.
  • Preferred an opioid compounds are morphine, codeine, meperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, bro pton's cocktail, naloxone, naltrexone, pentazocine, butorphanol, nabuphine, and buprenorphine.
  • Especially preferred opioid compounds are selected from the group consisting of hydromorphone, hydrocodone, meperidone, buprenorphine, butorphenol, nalbuphine, pentazocine, oxymorphine, oxycodone, l €ivorphanol, fentanyl, and alphaprodine.
  • Particularly preferred opioid compounds are selected from the group consisting of propoxyphene, methadone, morphine, hydrocodone, hydromorphine, and codeine.
  • the especially particularly preferred opioid compounds are selected from morphine and codeine.
  • a group of compounds having muscarinic cholinergic activity can be particular useful for treating pain when used in combination with non-steroidal antiinflammatory agents (NSAIDS) . More specifically, the invention provides a method of treating pain in humans using a specified known compounds (collectively referred to herein as "selected muscarinic compounds") in combination with a NSAIDS to provide a synergistic effect.
  • Selected Muscarinic compounds are believed to be active based on activity at muscarinic cholinergic receptors; however, the present invention is in no way limited by the mechanism of action.
  • NSAIDS There are many NSAIDS known in the literature and to the skilled artisan. We have discovered that a group of compounds having muscarinic cholinergic activity can be particular useful for treating pain when used in combination with acetaminophen. More specifically, the invention provides a method of treating pain in humans using a specified Selected Muscarinic Compounds in combination with acetaminophen to provide a synergistic effect.
  • the invention provides a method of treating pain in humans using Selected Muscarinic Compounds in combination with a central alpha-adrenergic active compound to provide a synergistic effect.
  • composition of this invention a Selected Muscarinic Compound and NSAIDS compound are combined in a weight ratio of Compound to NSAIDS of from about 1 to about 1000.
  • a preferred composition is a weight ratio of Compound to NSAIDS of from about 1 to about 100.
  • An especially preferred ratio is from about 1 to about 30.
  • a further preferred ratio may be from about 1 to about 10.
  • a final preferred ratio may be from about 1 to about 3.
  • a Selected Muscarinic Compound and acetaminophen are combined in a weight ratio of Selected Muscarinic Compound to acetaminophen of from about 1 to about 1000.
  • a preferred composition is a weight ratio of Selected Muscarinic Compound to acetaminophen of from about 1 to about 100.
  • An especially preferred ratio is from about 1 to about 30.
  • a further preferred ratio may be from about 1 to about 10.
  • a final preferred ratio may be from about 1 to about 3.
  • the Selected Muscarinic Compounds are effective over a wide dosage range,- however, it is desirable to administer a dosage that is as low as possible.
  • the amount of NSAIDS present in the composition is adjusted as described above in ratio to the Selected Muscarinic Compound dosage.
  • the amount of acetaminophen present in the composition is adjusted as described above in ratio to the Selected Muscarinic compound dosage.
  • composition of this invention a Selected Muscarinic Compound selected and one or more opioid compounds are combined in a weight ratio of Selected Muscarinic Compound to opioid compound of from about 1 to about 1000.
  • a preferred composition is a weight ratio of Selected Muscarinic Compound to opioid compound of from about 1 to about 100.
  • An especially preferred ratio is from about 1 to about 30.
  • a further preferred ratio may be from about 1 to about 10.
  • a final preferred ratio may be from about 1 to about 3.
  • the amount of opioid compound present in the composition is adjusted as described above in ratio to the Selected Muscarinic Compound dosage.
  • the amount of the Selected Muscarinic Compound actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of Selected Muscarinic Compound to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way.
  • the present compounds are preferably administered orally to humans susceptible to or suffering from pain
  • the compounds may also be administered by a variety of other routes such as the transdermal, parenterally, subcutaneous, intranasal, intramuscular and intravenous routes.
  • Such formulations may be designed to provide delayed or controlled release using formulation techniques which are known in the art.
  • Transdermal formulations containing the composition claimed herein most preferably deliver the active substances in an effective amount for from about three days to about seven days. However, for chronic pain such as arthritis or cancer pain, a transdermal delivery of from about three days to up to about two weeks is desirable. Alternatively, it may be preferred to deliver the claimed compositions transdermally in an effective amount for from about one day to about three days.
  • the term "treating" includes prophylaxis of a physical and/or mental condition or amelioration or elimination of the developed physical and/or mental condition once it has been established or alleviation of the characteristic symptoms of such condition.
  • the Selected Muscarinic Compounds employed in the invention are not believed to act via the
  • the activity of the present Selected Muscarinic Compounds as analgesic agents is believed to be based upon modulation of muscarinic cholinergic receptors.
  • the mechanism by which the present compounds function is not necessarily the mechanism stated supra . , and the present invention is not limited by any mode of operation.
  • Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar pharmaceutically-acceptable inorganic or organic acid addition salts, and include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) which are known to the skilled artisan.
  • the compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
  • the route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral or parenteral e.g. rectal, transdermal, depot, subcutaneous, intravenous, intramuscular or intranasal, the oral route being preferred.
  • the dosage administered will, of course, vary depending on known factors such as the pharmacodynamic characteristics of the particular agent, and its mode and route of administration; age, health, and weight of the recipient; nature and extent of the symptoms, kind of concurrent treatment, frequency of treatment, and the effect desired.
  • the daily dosage can be such that the active ingredient is administered at a daily dosage of from about 0.2 mg/kg to about 100 mg/kg of body weight SeLected Muscarinic Compound and from about 0.6 to about 200 mg/kg of NSAIDS.
  • compositions suitable for internal administration contain from about one half (0.5) milligrams to about 600 milligrams of active ingredient per unit.
  • the active ingredient will ordinarily be present in an amount of from about 0.5% to about 95% by weight based on the total weight of the composition.
  • the daily dosage can be such that the active ingredient is administered at a daily dosage of from about 0.2 mg/kg to about 500 mg/kg of body weight Selected Muscarinic Compound and from about 0.6 to about 200 mg/kg of acetaminophen.
  • compositions include a compound of Selected Muscarinic Compound and one or more NSAIDSs, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container.
  • a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container.
  • the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container.
  • the carrier When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound.
  • the active compound can be adsorbed on a granular solid container for example in a sachet.
  • suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone.
  • the formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring agents.
  • the formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
  • compositions include a Selected Muscarinic Compound and acetaminophen, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container.
  • a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container.
  • a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container.
  • a preferred composition is a weight ratio of
  • Selected Muscarinic Compound to central alpha-adrenergic active compound of from about 1 to about 100.
  • An especially preferred ratio is from about 1 to about 30.
  • a further preferred ratio may be from about 1 to about 10.
  • a final preferred ratio may be from about 1 to about 3.
  • the Selected Muscarinic Compounds are effective over a wide dosage range; however, it is desirable to administer a dosage that is as low as possible.
  • the amount of central alpha-adrenergic active compound present in the composition is adjusted as described above in ratio to the Selected Muscarinic Compound dosage.
  • the daily dosage can be such that the active ingredient is administered at a daily dosage of from about 0.2 mg/kg to about 500 mg/kg of body weight Selected Muscarinic ompound and from about 0.6 to about 200 mg/kg of central alpha-adrenergic active compound.
  • compositions include a Selected Muscarinic Compound and one or more central alpha- adrenergic active compounds, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container.
  • a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container.
  • conventional techniques for the preparation of pharmaceutical compositions may be used.
  • the pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compounds.
  • auxiliary agents emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compounds.
  • injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
  • Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application.
  • Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch.
  • a syrup or elixir can be used in cases where a sweetened vehicle can be employed.
  • compositions of this invention are dispensed in unit form comprising from about 0.1 to about 300 mg in a pharmaceutically acceptable carrier per unit dosage.
  • compositions of this invention may be suitable for administration to an animal.
  • animals include both domestic animals, for example livestock, laboratory animals, and household pets, and non-domestic animals such as wildlife. More preferredly, the animal is a vertebrate.
  • a composition of this invention shall be administered to a mammal. It is especially preferred that the animal is a domestic mammal or a human. The most preferred mammal is a human. For such domestic animal purposes, a composition of this invention may be administered as a feed additive.
  • Acetic acid-induced writhing A standard procedure for detecting and comparing the analgesic activity of different classes of analgesic drugs for which there is a good correlation with human analgesic activity is the prevention o acetic acid-induced writhing in mice. Mice, are subcutaneously administered various doses of the claimed composition and are injected injected intraperitoneally with acetic acid (0.5% solution, 10 ml/kg) 5 min prior to a designated observation period. For scoring purposes a
  • writhe is indicated by whole body stretching or contraction of the abdomen during the observation period beginning 5 min after receiving the acetic acid. Inhibition of writhing behavior is demonstrative of analgesic activity. See, Haubrich, D.R., Ward, S.J., Baizman, E., Bell, M.R. , Bradford, J., Ferrari, R., Miller, M. , Perrone, M. , Pierson, A.K., Saelens, J.K. and Luttinger, D. : Pharmacology of pravadoline: a new analgesic agent. The Journal of Pharmacology and Experimental Therapeutics 255 (1990) 511-522.
  • Sciatic nerve ligation model Rats are anesthetized and a nerve ligation procedure performed. The common sciatic nerve is exposed and 4 ligatures tied loosely around it with about 1 mm spacing. One day to 10 weeks after surgery, the nociceptive testing is performed. Responses to noxious heat are determined by placing the rats in a chamber with a clear glass floor and aiming at the plantar surface of the affected foot a radiant heat source from beneath the floor. Increased latency to withdraw the hindpaw is demonstrative of analgesic activity.
  • Rats are anesthetized and when there is a loss of spontaneous movement the rats are injected subcutaneously in the dorsal surface of the hindpaw with 50 ul of 5% formalin solution using a 30 gauge needle. Rats are then individually placed in an open Plexiglas chamber for observation, and within a maximum interval of 1 to 2 min, the animal displays recovery from anesthesia with spontaneous activity and normal motor function.
  • Pain behavior is quantified by periodically counting the incidents of spontaneous flinching/shaking of the injected paw. The flinches are counted for 1-min periods at 1- to 2-, 5- to 6- and 5min intervals during the interval from 10 to 60 min. Inhibition of the pain behavior is demonstrative of an analgesic activity.
  • mice Male mice are fasted for 16-22 hours and weighed. Mice weighing from about 18-22 grams at the time of testing are used for the following studies. All mice are dosed sequentially by the oral route with suspensions of a composition of this invention. Doses are coded using a code unknown to the observer.
  • a stock suspension of the test composition is prepared by mixing the active ingredients with about 40 mL of an aqueous vehicle containing about 2% Tween 80 (R) , a pharmacological dispersant and containing 100% polysorbate 80, and 1% by weight Methocel (R) MC powder, and containing 100% methylcellulose, in distilled water. The mixture may be sonicated for about 10 to about 15 seconds using an ultrasound sytem. All dosing suspensions are prepared by dilution of the stock suspension with Methocel/Tween 80. All suspensions are used within two hours of preparation.
  • mice An accepted standard for detecting and comparing the analgesic activity of different classes of analgesic compounds for which there is a good correlation with human analgesic activity is the prevention of phenyl-p- benzoquinone induced writhing in mice. [H. Blumberg et al. Proc. Soc. Exp. biol. Med., 118, 763-766 (1965)] . Mice, treated with various doses of Selected Muscarinic Compound, composition or vehicle are injected intraperitoneally with a standard challenge dose of phenyl- p-benzoquinone 5 minutes prior to a designated observation period.
  • the pheyl-p-benzoquinone is prepared as about 0.1 mg/ml solution in about 5% by volume of ethanol in water.
  • the writhing dose is 1.25 mg/kg injected at a volume of about 0.25ml/10g.
  • a "writhe" is indicated by whole body stretching or contracting of the abdomen during an observation period beginning about five minutes after the phenyl-p-benzoquinone dose.
  • Analgesic as claimed herein represents the "ED50 addition line" which indicates the expected location of the ED50' ⁇ for Selected Muscarinic Compound and classical analagesic combinations if simple additivity were to describe their combined effects.
  • the 95% confidence range for the ED50 addition line is shown by the area between the broken lines above and below the ED50 addition line.
  • Muscarinic Compound and Synergistic Analgesic component of each fixed dosage ratio would be contained within or overlap the region of the ED50 addition line.
  • Combination ED50's located significantly below the ED50 addition line would represent unexpectedly enhanced analgesic activity and combination ED50's located above the line would represent unexpected diminished analgesic effect.
  • One method to establish the significance of such unexpected enhanced or diminished activity is to calculate the best fitting polynomial regression line to the observed ED50's using standard mathematical techniques. Such experiments demonstrate that compositions comprised of a Selected Muscarinic Compound and one or more Synergistic Analgesics provides a statistically significant synergistic analgesic effect.
  • Preferred compounds for use in treating pain include:
  • Examples of preferred compounds include, but are not limited to, 3- [2- ( ⁇ -hydroxypyrazin)yl] -1- azabicyclo[2.2.2]octane, 3- (2-pyrazinyl) -1- azabicyclo [2.2.1]heptane, 6- (2-pyrazinyl) -1- azabicyclo[3.2.1]octane, 6- (2-pyrazinyl) -1- azabicyclo[3.2.l]octan-6-ol, 3-fluoro-3- (2-pyrazinyl) -1- azabicyclo[2.2.1]heptane, 1-methyl-3- (2- pyrazinyl)pyrrolidine, 3- [2- (3-methylpyrazin)yl] -1- azabicyclo[2.2.2]octan-3-ol, 3- [2- (3 , 6-dimethylpyrazin)yl] -1- azabicyclo[2.2.1]heptane, 3- [2- (6-allyloxypyra

Abstract

The present invention provides a composition and method for treating pain using a composition comprising Selected Muscarinic Compounds and one or more compounds selected from the group consisting of Nonsteroidal Antiinflammatory drugs, acetaminophen, opioids, and alpha-adrenergic compounds.

Description

COMPOSITION FOR TREATING PAIN
The present invention relates to a method for using a combination of compounds for treating pain.
This invention relates to a therapeutic combination of compounds to provide analgesic activity.
More active analgesic combinations effects are in constant demand because they offer the attractive possibility of relieving pain with reduced dosages, thereby diminishing the expected side effects and toxicity that would otherwise result from higher dosages. It would be particularly desirable to acquire a synergistic combination effect. Such a composition is the subject of the present invention.
The composition of this invention provides a surprising synergistically effective treatment for pain using compounds which are independently known in the art. The synergistic effect of the present composition provides a means for treating pain using a lower dosage of each compound in the composition, thus providing a treatment with a more desirable side effect profile.
The present invention provides a composition useful for the treatment of pain, comprising a compound selected from the group consisting of:
Figure imgf000003_0001
wherein R1 is hydrogen, Ci-Cδ alkyl or phenyl-Cι-C4 alkyl, in which the phenyl group may be substituted with halogen, C1-C4 alkyl or C1-C4 alkoxy;
R2 is Ci-Cδalkyl, C3-C6 alkenyl, C3-C6 alkynyl, branched or unbranched with 1-6 carbon atoms inclusive, which group may be optionally substituted with fluoro, hydroxy or phenyl optionally substituted with fluoro, trifluoromethyl, lower alkyl, hydroxy, or lower alkoxy;
R3 and R4 are independently hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, phenyl optionally substituted with halogen trifluroromethyl, C1-C4 alkyl, hydroxy, or C1-C4 alkoxy, or phenyl-Cι-C4 alkyl, in which the phenyl group may be substituted with halogen, C1-C4 alkyl or C1-C4 alkoxy;
Figure imgf000004_0001
in which R5 represents the radical
Figure imgf000004_0002
in which R6 at any position on the benzene ring represents linear, branched or cyclic Ci-Cβ alkyl, C2-C8 alkenyl or C2- C8 alkynyl or the radical
N-R»
in which R7 and R8 which may be identical or different represent hydrogen, linear C3.-C8 alkyl, C2-C8 alkenyl or C2- CΘ alkynyl or form together with the nitrogen atom to which they are attached a carbonaceous hetercyclic radical optionally containing another heteroatom, or the radical OR9,
R9 representing hydrogen, linear, branched or cyclic Ci-Cβ alkyl, C2-C8 alkenyl or C2-C8 alkynyl or aryl containing up to 14 carbon atoms, or the radical SR10 or S(0)R1:L, R10 and
R11 represent linear, branched or cyclic Ci-Cβ alkyl, C2-C8 alkenyl or C2-C8 alkynyl, or R5 represents naphthyl optionally substituted with R6' ' R6' being defined above for R6;
Figure imgf000005_0001
in which R12 represents the radical
Figure imgf000005_0002
in which R13 at any position on the benzene ring represents linear, branched or cyclic Ci-Cs alkyl, C2-C8 alkenyl or C2- C8 alkynyl or the radical
Figure imgf000005_0003
in which R14 and R15 which may be identical or different represent hydrogen, linear Cχ-C8 alkyl, 2-C8 alkenyl or C2- Cδ alkynyl or form together with the nitrogen atom to which they are attached a carbonaceous hetercyclic radical optionally containing another heteroatom, or the radical or O2, or OR12', R12' representing hydrogen, linear, branched or cyclic Ci-Cβ alkyl, C2-C8 alkenyl or C2-C8 alkynyl or aryl containing up to 14 carbon atoms, or the radical SR16 or S(0)R17, R16 and R17 represent linear, branched or cyclic Cτ_- C8 alkyl, C2-C8 alkenyl or C2-Cg alkynyl, or R12 represents naphthyl optionally substituted with R13 ' - R13' being defined above for R13;
Figure imgf000006_0001
wherein, one of R18, R19, and R20 represents nitrogen and the remainder represent carbon atoms; substituted on one of the ring carbon atoms with a R24 substituent represented by a non¬ aromatic azacyclic or azabicyclic ring system and independently substituted on each of the other ring carbon atoms with R23, R21, or R22 substituent of low lipophilicity or a hydrocarbon having a maximum of 20 carbon atoms;
Figure imgf000006_0002
wherein one of R28, R29 or R30 is an oxygen atom and the other two are nitrogen atoms, and the dotted circle represents aromaticity (two double bonds) thus forming a 1, 3, 4-oxadiazole or 1, 2, 4-oxadiazole nucleus; R31 represents a non-aromatic '927azacycle or ' 927azabicyclic ring system; and R32 represents a substituent which is convertable in vivo to an amino group;
Figure imgf000006_0003
VI; wherein R34 represents a non-aromatic; non-fused 1- azabicyclic ring system; and
R35, R36, and R37 independently represent hydrogen, F, Cl, Br, -CF3, -OR38, - R38R39, -NHOR38, - HNH2, -CN, COR40, or a substituted or unsubstituted, saturated or unsaturated hydrocarbon group, provided that at least one of R35, R36, and R37 is other than hydrogen or a hydrocarbon group, or R35 and R36 or R37 taken together form a Cι_6alkylenedioxy ring, wherein R38 is Ci-βalkyl, C2-6alkenyl or C2-6alkynyl, R39 is hydrogen, Cι_g alkyl,or -COCH3, and R40 represents OH, -OR38, NHR39, or -NR38R39
Figure imgf000007_0001
wherein R43 is alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to six carbon atoms, alkenyl of from two to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to six carbon atoms, alkynyl of from two to six carbon atoms, substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms,
(CH2)
Figure imgf000007_0002
wherein n is zero or an integer of one to eight and R47 and R48 are independently hydrogen, fluorine, chlorine, bromine, hydroxy, alkyl of from one to three carbon atoms, or alkoxy of from one to three carbon atoms, or alkoxy of from one to four carbon atoms, or
Figure imgf000008_0001
wherein
R47 and R48 are as defined above; X is oxygen or sulfur;
R44 is alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms alkenyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or
Figure imgf000008_0002
wherein n, R47 and R48 are as defined above R45 and R46 are each independently hydrogen, alkyl of from one to twenty carbon atoms, alkyl of from one to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to twenty carbon atoms, alkenyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to twenty carbon atoms, alkynyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to eight carbon atoms, phenyl, phenyl substituted with alkyl of from one to four carbon atoms, alkyl of from one to four carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkoxy of from one to four carbon atoms, chlorine, bromine, hydroxy, nitro or trifluoromethyl of R45 and R46 are taken together with the nitrogen atom to which they are attached to form a ring denoted by
Figure imgf000009_0001
wherein R49 is hydrogen, alkyl of from one to ten carbon atoms, alkyl of from one to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to ten carbon atoms, alkenyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms and n is as defined above,
Figure imgf000010_0001
wherein X is defined above or
Figure imgf000010_0002
wherein R50 is hydrogen or alkyl of from one to six carbon atoms,
Figure imgf000010_0003
wherein R51 is selected from the group consisting of
Figure imgf000011_0001
R52 is hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms or aryl; n' is zero or an integer of one or two; X' is carbon or nitrogen; and ... represents a single or double bond with the proviso that when, ____ represents a double bond X1 is nitrogen and when _____ represents a single bond X' is CH2;
Figure imgf000012_0001
wherein R53 is selected from the group consisting
Figure imgf000012_0002
R54, R55, R56, and R57 are each independenty hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms, phenyl or phenyl substituted by one to four substituents selected from C1-C10 alkyl, alkoxy, C1-C10 halogen or trifluoromethyl; n1 is an interger of one or two;
Figure imgf000012_0003
wherein X is oxygen, sulfur, or -N-Rδ2, wherein R62 is hydrogen or alkyl of from one to ten carbon atoms; R58 is selected from the group consisting of
Figure imgf000013_0001
R59, R60, and R61 are each independently hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms or aryl; represents a single or double bond with the proviso that when represents a double bond R57 and R60 are absent;
Figure imgf000014_0001
wherein R63, R64, and R65 are each independently hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms, phenyl or phenyl substituted by one to four substituents selected from the group consisting of alkyl, alkoxy, thioalkoxy, halogen, and trifluoromethyl; R66 is hydrogen, hydroxy or alkoxy of from one to ten carbon atoms; and R67 is selected from the group consisting of
Figure imgf000014_0002
Figure imgf000014_0003
Figure imgf000014_0004
Figure imgf000015_0001
wherein
R69 is hydrogen and R67 is hydrogen, alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms, alkenyl of from three to six carbon atoms, substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or
R68 and R69 are taken together with the nitrogen atom to which they are attached to form a ring denoted by
Figure imgf000015_0002
wherein n' is zero or an integer from one to eight and R73 is hydrogen, alkyl of from one to ten carbon atoms, alkyl of from one to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to ten carbon atoms, alkenyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to ten carbon atoms or alkynyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms; R70 is hydrogen, alkyl of from one to six carbon atoms, alkyl of form one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms, alkenyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or R70 when taken together with R68 forms a ring denoted by
wherein n is an integer from one to three and R68 are as defined above;
R71 and R72 are each independently hydrogen, alkyl of from one to twenty carbon atoms, alkyl of from one to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to twenty carbon atoms, alkenyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to twenty carbon atoms, alkynyl of from three to twenty carbon atoms substituted with dydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to eight carbon atoms, phenyl, phenyl substituted with alkyl of from one to four carbon atoms, alkyl of from one to four carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkoxy of from one to four carbon atoms, chlorine, bromine, hydroxy, nitro or trifluoromethyl of R3 and R4 are taken together with the nitrogen atom to which they are attached to form a ring denoted by
Figure imgf000017_0001
wherein n' and R73 are ad defined above,
Figure imgf000017_0002
wherein X is defined above or
Figure imgf000017_0003
wherein R74 is hydrogen or alkyl of from one to six carbon atoms,
Figure imgf000017_0004
in which Z is a heterocyclic group
Figure imgf000018_0001
in which Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, or three nitrogen atoms, any amino nitrogen being substituted by a Cι-2 alkyl, cyclopropyl or propargyl group, and any ring carbon atom being optionally substituted by a group Rx; or a group
Figure imgf000018_0002
in which Ai, A2 and A3 complete a 5-membered aromatic ring and Ai is oxygen or sulphur, one of A2 and A3 is CR2 and the other is nitrogen or CR3, or A2 is oxygen or sulphur, one of Ai and A3 is CR2 and the other is CR3; and Ri, R2 and R3 are independently selected from hydrogen, halogen, CN, OR4, SR4, N(R.ι)2, NHCOR4, NHCOOCH3, NHCOOC2H5, NHOR4, NHNH , N02, COR4, COR13, cyclopropyl, C2-5 straight chain alkenyl, C2-5 straight chain alkynyl or C1-5 straight chain alkyl optionally terminally substituted with OR4, (R )2» SR4, CO2R4, CON(R4)2 or one, two or three halogen atoms, in which each R4 is independently hydrogen or C1-3 alkyl and R5 is OR4, H2 or NHR4; or in which Z is a group -C(R7)=NRβ in which R is a group ORQ , where Rβ is Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, a group OCOR9 where R9 is hydrogen or Rs, or a group NHR;LO or NR11R12 where Rio- Rll and R12 are independently Ci- 2 alkyl and R7 is hydrogen or C1-4 alkyl, subject to the proviso that when R6 is a group OCORg or NHR10, R7 is C1-4 alkyl
Figure imgf000019_0001
in which one of X and Y represents hydrogen and the other represents Z, and Z' is a group
Figure imgf000019_0002
in which Q' represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises two or three nitrogen atoms, any amino nitrogen being substituted by a Cl-2 alkyl, cyclopropyl or propargyl group, r represents the integer of 2 or 3, ε represents an integer of 1 or 2 and t represents 0, with the proviso that when Y is hydrogen s is 1;
Figure imgf000019_0003
wherein R75 represents
Figure imgf000020_0001
in which each of p and q independently represents an integer of 2 to 4, r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;
R76 is a group OR78, where R78 is Cι_4 alkenyl, C2-4 alkynyl, a group OCOR79 where R79 is hydrogen or R78, or a group NHR80 or NR81, R82, where R80, R81 and R82 are independently C1-2 alkyl; and R77 is hydrogen or Cι_4alkyl, subject to the proviso that when R76 is a group OCOR79 or a group NHR80, R77 is alkyl;
(3R, 4R) -3- (3-cyclopropyl-1, 2, 4-oxadiazol-5-yl) -1- azabicyclo [2.2. lheptane; or a pharmaceutically acceptable salt or solvate thereof; and one or more Synergistic Analgesics in a weight ratio of
Compound to Synergistic Analgesic of from about 1 to about
1000.
The present invention provides a method for treating pain comprising administering to a patient in need thereof, an anagesic composition comprising a compound selected from the group consisting of:
Figure imgf000021_0001
wherein R1 is hydrogen, Cχ-C6 alkyl or phenyl-Cι-C4 alkyl, in which the phenyl group may be substituted with halogen, C1-C4 alkyl or C1-C4 alkoxy;
R2 is Ci-Cgalkyl, C3-C6 alkenyl, C3-C6 alkynyl, branched or unbranched with 1-6 carbon atoms inclusive, which group may be optionally substituted with fluoro, hydroxy or phenyl optionally substituted with fluoro, trifluoromethyl, lower alkyl, hydroxy, or lower alkoxy;
R3 and R4 are independently hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, phenyl optionally substituted with halogen trifluroromethyl, C1-C4 alkyl, hydroxy, or C1-C4 alkoxy, or phenyl-Cι-C4 alkyl, in which the phenyl group may be substituted with halogen, C1-C4 alkyl or C1-C4 alkoxy;
Figure imgf000021_0002
in which R5 represents the radical
Figure imgf000021_0003
in which R6 at any position on the benzene ring represents linear, branched or cyclic Ci-Cs alkyl, C2-C8 alkenyl or C2- CQ alkynyl or the radical N
in which R7 and R8 which may be identical or different represent hydrogen, linear Ci-Cs alkyl, C2-C8 alkenyl or C2- Cδ alkynyl or form together with the nitrogen atom to which they are attached a carbonaceous hetercyclic radical optionally containing another heteroatom, or the radical OR9, R9 representing hydrogen, linear, branched or cyclic Ci-Cβ alkyl, C2-C8 alkenyl or C2-C8 alkynyl or aryl containing up tc 14 carbon atoms, or the radical SR10 or S{0)R1:L, R10 and R11 represent linear, branched or cyclic Ci-Cβ alkyl, C2-C8 alkenyl or C2-C8 alkynyl, or R5 represents naphthyl optionally substituted with R6'< R6' being defined above for R6;
Figure imgf000022_0001
in which R12 represents the radical
Figure imgf000022_0002
in which R13 at any position on the benzene ring represents linear, branched or cyclic Ci-Cβ alkyl, C2-C8 alkenyl or C2- Cβ alkynyl or the radical
Figure imgf000022_0003
in which R14 and R15 which may be identical or different represent hydrogen, linear C -Cβ alkyl, C2-C8 alkenyl or C2' Cs alkynyl or form together with the nitrogen atom to which they are attached a carbonaceous hetercyclic radical optionally containing another heteroatom, or the radical or NO2, or OR12', R12 ' representing hydrogen, linear, branched or cyclic Ci-Ce alkyl, C2-C8 alkenyl or C2-C8 alkynyl or aryl containing up to 14 carbon atoms, or the radical SR16 or S(0)R17, R16 and R17 represent linear, branched or cyclic Cι~ Cβ alkyl, C2-C8 alkenyl or C2-C8 alkynyl, or R12 represents naphthyl optionally substituted with R13 ' ' R13' being defined above for R13;
Figure imgf000023_0001
wherein, one of R18, R19, and R20 represents nitrogen and the remainder represent carbon atoms; substituted on one of the ring carbon atoms with a R24 substituent represented by a non¬ aromatic azacyclic or azabicyclic ring system and independently substituted on each of the other ring carbon atoms with R23, R21, or R22 substituent of low lipophilicity or a hydrocarbon having a maximum of 20 carbon atoms;
Figure imgf000023_0002
wherein one of R28, R29 or R30 is an oxygen atom and the other two are nitrogen atoms, and the dotted circle represents aromaticity (two double bonds) thus forming a
1, 3, 4-oxadiazole or 1, 2, 4-oxadiazole nucleus; R31 represents a non-aromatic '927azacycle or ' 927azabicyclic ring system; and R;i2 represents a substituent which is convertable in vivo to an amino group;
Figure imgf000024_0001
wherein R34 represents a non-aromatic; non-fused 1- azabicyclic ring system; and
R35, R36, and R37 independently represent hydrogen, F, Cl, Br, -CF3, -OR38, -NR38R39, -NHOR38, -NHNH , -CN, COR40, or a substituted or unsubstituted, saturated or unsaturated hydrocarbon group, provided that at least one of R35, R36, and R37 is other than hydrogen or a hydrocarbon group, or R35 and R35 or R37 taken together form a Ci-galkylenedioxy ring, wherein R38 is Cι_6alkyl, C2~6alkenyl or C2-6alkynyl, R39 is hydrogen, Cι-6 alkyl,or -COCH3, and R40 represents OH, -OR38, NHR39, or -NR38R39
Figure imgf000024_0002
wherein R43 is alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to six carbon atoms, alkenyl of from two to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to six carbon atoms, alkynyl of from two to six carbon atoms, substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms,
Figure imgf000025_0001
wherein n is zero or an integer of one to eight and R47 and R48 are independently hydrogen, fluorine, chlorine, bromine, hydroxy, alkyl of from one to three carbon atoms, or alkoxy of from one to three carbon atoms, or alkoxy of from one to four carbon atoms, or
Figure imgf000025_0002
wherein
R47 and R48 are as defined above;
X is oxygen or sulfur;
R44 is alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms alkenyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or
Figure imgf000026_0001
wherein n, R47 and R48 are as defined above R45 and R46 are each independently hydrogen, alkyl of from one to twenty carbon atoms, alkyl of from one to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to twenty carbon atoms, alkenyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to twenty carbon atoms, alkynyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to eight carbon atoms, phenyl, phenyl substituted with alkyl of from one to four carbon atoms, alkyl of from one to four carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkoxy of from one to four carbon atoms, chlorine, bromine, hydroxy, nitro or trifluoromethyl of R45 and R46 are taken together with the nitrogen atom to which they are attached to form a ring denoted by
Figure imgf000026_0002
wherein R49 is hydrogen, alkyl of from one to ten carbon atoms, alkyl of from one to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to ten carbon atoms, alkenyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms and n is as defined above,
Figure imgf000027_0001
wherein X is defined above or
Figure imgf000027_0002
wherein R50 is hydrogen or alkyl of from one to six carbon atoms,
Figure imgf000027_0003
wherein R51 is selected from the group consisting of
Figure imgf000028_0001
R52 is hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms or aryl; n' is zero or an integer of one or two; X' is carbon or nitrogen; and ... represents a single or double bond with the proviso that when, _____ represents a double bond X' is nitrogen and when .. t represents a single bond X' is CH2;
Figure imgf000029_0001
wherein R53 is selected from the group consisting
Figure imgf000029_0002
H i
CH3
R54, R55, R56, and R57 are each independenty hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms, phenyl or phenyl substituted by one to four substituents selected from C1-C10 alkyl, alkoxy, C1-C10 halogen or trifluoromethyl; n' is an interger of one or two;
Figure imgf000029_0003
wherein X is oxygen, sulfur, or -N-R62, wherein R62 is hydrogen or alkyl of from one to ten carbon atoms; R58 is selected from the group consisting of
Figure imgf000030_0001
Figure imgf000030_0002
Figure imgf000030_0003
R59 , R60, and R61 are each independently hydrogen, alkyl of froti one to ten carbon atoms, alkynyl of from two to ten carbon atoms or aryl; represents a single or double bond witn the proviso that when represents a double bond R57 and R60 are absent;
Figure imgf000031_0001
wherein R63, R64, and R65 are each independently hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms, phenyl or phenyl substituted by one to four substituents selected from the group consisting of alkyl, alkoxy, thioalkoxy, halogen, and trifluoromethyl; R66 is hydrogen, hydroxy or alkoxy of from one to ten carbon atoms; and RG7 is selected from the group consisting of
Figure imgf000031_0002
Figure imgf000031_0003
Figure imgf000031_0004
CH3
Figure imgf000032_0001
wherein
R69 is hydrogen and R67 is hydrogen, alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms, alkenyl of from three to six carbon atoms, substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or
R6i3 and R69 are taken together with the nitrogen atom to which they are attached to form a ring denoted by
Figure imgf000032_0002
wherein n' is zero or an integer from one to eight and R73 is hydrogen, alkyl of from one to ten carbon atoms, alkyl of from one to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to ten carbon atoms, alkenyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to ten carbon atoms or alkynyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms; R70 is hydrogen, alkyl of from one to six carbon atoms, alkyl of form one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms, alkenyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or R70 when taken together with R68 forms a ring denoted by
Figure imgf000033_0001
n
wherein n is an integer from one to three and R68 are as defined above;
R71 and R72 are each independently hydrogen, alkyl of from one to twenty carbon atoms, alkyl of from one to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to twenty carbon atoms, alkenyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to twenty carbon atoms, alkynyl of from three to twenty carbon atoms substituted with dydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to eight carbon atoms, phenyl, phenyl substituted with alkyl of from one to four carbon atoms, alkyl of from one to four carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkoxy of from one to four carbon atoms, chlorine, bromine, hydroxy, nitro or trifluoromethyl of R3 and R4 are taken together with the nitrogen atom to which they are attached to form a ring denoted by
Figure imgf000034_0001
wherein n" and R73 are ad defined above,
Figure imgf000034_0002
wherein X is defined above or
Figure imgf000034_0003
wherein R74 is hydrogen or alkyl of from one to six carbon atoms.
Figure imgf000034_0004
in which Z is a heterocyclic group
Figure imgf000035_0001
in which Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, or three nitrogen atoms, any amino nitrogen being substituted by a Cι-2 alkyl, cyclopropyl or propargyl group, and any ring carbon atom being optionally substituted by a group Ri; or a group
Figure imgf000035_0002
in which Ai, A2 and A3 complete a 5-membered aromatic ring and Ai is oxygen or sulphur, one of A2 and A3 is CR2 and the other is nitrogen or CR3, or A2 is oxygen or sulphur, one of Ai and A3 is CR2 and the other is CR3; and Ri, R2 and R3 are independently selected from hydrogen, halogen, CN, OR4, SR4, (R4)2» NHCOR4, NHCOOCH3, NHCOOC2H5, NHOR4, NHNH2, NO2, COR4, COR5, cyclopropyl, C2-5 straight chain alkenyl, C2-5 straight chain alkynyl or C1-5 straight chain alkyl optionally terminally substituted with OR4, N(R )2/ SR4, CO2R4, CON(R4)2 or one, two or three halogen atoms, in which each R4 is independently hydrogen or C1-3 alkyl and R5 is OR , NH2 or NHR4; or in which Z is a group -C(R7)=NRβ in which R is a group OR8, where R8 is C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, a group OCOR9 where R9 is hydrogen or R8, or a group NHR10 or R11R12 where RlO- Rll and R12 are independently C__- 2 alkyl and R7 is hydrogen or C1-4 alkyl, subject to the proviso that when Rζ is a group OCOR9 or NHR10, 7 is C1-4 alkyl
Figure imgf000036_0001
in which one of X and Y represents hydrogen and the other represents Z, and Z' is a group
Figure imgf000036_0002
in which Q' represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises two or three nitrogen atoms, any amino nitrogen being substituted by a Cl-2 alkyl, cyclopropyl or propargyl group, r represents the integer of 2 or 3 , s represents an integer of 1 or 2 and t represents 0, with the proviso that when Y is hydrogen s is 1;
Figure imgf000036_0003
wherein R75 represents
Figure imgf000037_0001
in which each of p and q independently represents an integer of 2 to 4, r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;
R76 is a group OR78, where R78 is C1-4 alkenyl, C2-4 alkynyl, a group OCOR79 where R79 is hydrogen or R78, or a group NHR80 or NR81, R82, where R80, R81 and R82 are independently C1-2 alkyl; and R77 is hydrogen or Cι-4alkyl, subject to the proviso that when R76 is a group OCOR79 or a group NHR80, R77 is alkyl;
(3R, 4R) -3- (3-cyclopropyl-l, 2 , 4-oxadiazol-5-yl) -1- azabicyclo [2.2. lheptane; or a pharmaceutically acceptable salt or solvate thereof; and one or more Synergistic Analgesics in a weight ratio of
Compound to Synergistic Analgesic of from about 1 to about
1000.
As noted hereinbefore, the compounds employed in the method of the present invention are known. The compounds, methods of preparing the compounds, as well as pharmaceutical formulations containing the compounds, are taught in U.S. Pat. Nos. 4,923,880, 5,110,828, 5,041,436, 5,278,170, 7,177,084, 4,992,436, 5,260,293, 4996,201, 5,066,662, 5,066,665, 5,066,663, 4,988,688, 5,106,853, 5,192,765, 5,041,455, 5,043,345, 5,260,314, 5,310,911, 5,106,851, 5,068,237, 5,318,978, 5,242,927, 5,300,516, 5,089,505, 5,302595, 5,219,871, 5,096,890, 5,164,386, 5,164,514, 5,157,160, 5,217,975, and 5,081,130 herein incorporated by reference.
It is to be understood that the invention extends to the use of each of the stereoisomeric forms of the compounds of the present invention as well as the pure diastereomeric, pure enantiomeric, and racemic forms of the named compounds.
As used herein, the terms "Synergistic Analgesic" and "Synergistic Analgesics" refer to the group consisting of Nonsteroidal anti-inflammatory drugs (NSAIDS) , acetaminophen, alpha-adrenergic compounds, and opioids. As used herein, the term "Selected Muscarinic
Compound" and "Selected Muscarinic Compounds" refers to a compound selected from the group consisting of
Figure imgf000038_0001
wherein R1 is hydrogen, C -Cδ alkyl or phenyl-Cι-C4 alkyl, in which the phenyl group may be substituted with halogen, C1-C4 alkyl or C1-C4 alkoxy;
R2 is C -Cgalkyl, C3-C6 alkenyl, C3-C6 alkynyl, branched or unbranched with 1-6 carbon atoms inclusive, which group may be optionally substituted with fluoro, hydroxy or phenyl optionally substituted with fluoro, trifluoromethyl, lower alkyl, hydroxy, or lower alkoxy;
R3 and R4 are independently hydrogen, Ci-Cβ alkyl, C3-C6 cycloalkyl, phenyl optionally substituted with halogen trifluroromethyl, C1-C4 alkyl, hydroxy, or C -C4 alkoxy, or phenyl-Cι~C4 alkyl, in which the phenyl group may be substituted with halogen, C1-C4 alkyl or C -C4 alkoxy; 37 -
Figure imgf000039_0001
in which R5 represents the radical
Figure imgf000039_0002
in which R6 at any position on the benzene ring represents linear, branched or cyclic Ci-Cs alkyl, C2-C8 alkenyl or C2- Cβ alkynyl or the radical
N-R»
in which R7 and R8 which may be identical or different represent hydrogen, linear Ci-Cβ alkyl, C2-C8 alkenyl or C2- Cβ alkynyl or form together with the nitrogen atom to which they are attached a carbonaceous hetercyclic radical optionally containing another heteroatom, or the radical OR9, R9 representing hydrogen, linear, branched or cyclic Cι~Cβ alkyl, C2~Ce alkenyl or C2~Cβ alkynyl or aryl containing up to 14 carbon atoms, or the radical SR10 or S(0)R1]-, R10 and R11 represent linear, branched or cyclic Ci-Cs alkyl, C2~Cδ alkenyl or C2~Cδ alkynyl, or R5 represents naphthyl optionally substituted with R6'- R6' being defined above for R6;
Figure imgf000039_0003
in which R12 represents the radical
Figure imgf000040_0001
in which R13 at any position on the benzene ring represents linear, branched or cyclic Ci-Cs alkyl, C2~Cδ alkenyl or C2- CQ alkynyl or the radical
Figure imgf000040_0002
in which R14 and R15 which may be identical or different represent hydrogen, linear C -Cδ alkyl, C2-Cβ alkenyl or C2- Cβ alkynyl or form together with the nitrogen atom to which they are attached a carbonaceous hetercyclic radical optionally containing another heteroatom, or the radical or O , or OR12', R12' representing hydrogen, linear, branched or cyclic Ci-Cs alkyl, C2~Ce alkenyl or C2-C8 alkynyl or aryl containing up to 14 carbon atoms, or the radical SR16 or S(0)R17, R16 and R17 represent linear, branched or cyclic C ~ Cδ alkyl, C2~Cβ alkenyl or C2-C8 alkynyl, or R12 represents naphthyl optionally substituted with R13 ' - R13' being defined above for R13;
Figure imgf000040_0003
wherein, one of R18, R19, and R20 represents nitrogen and the remainder represent carbon atoms; substituted on one of the ring carbon atoms with a R24 substituent represented by a non¬ aromatic azacyclic or azabicyclic ring system and independently substituted on each of the other ring carbon atoms with R23, R21, or R22 substituent of low lipophilicity or a hydrocarbon having a maximum of 20 carbon atoms;
Figure imgf000041_0001
wherein one of R28, R29 or R30 is an oxygen atom and the other two are nitrogen atoms, and the dotted circle represents aromaticity (two double bonds) thus forming a 1,3, 4-oxadiazole or 1, 2, 4-oxadiazole nucleus; R31 represents a non-aromatic ' 927azacycle or ' 27azabicyclic ring system; and R32 represents a substituent which is convertable in vivo to an amino group;
Figure imgf000041_0002
wherein R34 represents a non-aromatic; non-fused 1- azabicyclic ring system; and
R35, R36, and R37 independently represent hydrogen, F, Cl, Br, -CF3, -OR38, -NR38R39, -NHOR38, -NHNH2, -CN, COR40, or a substituted or unsubstituted, saturated or unsaturated hydrocarbon group, provided that at least one of R35, R36, and R37 is other than hydrogen or a hydrocarbon group, or R35 and R36 or R37 taken together form a Cι-6alkylenedioxy ring, wherein R38 is Ci-βalkyl, C2-6 lkenyl or C2-6 lkynyl, R39 is hydrogen, C _6 alkyl,or -COCH3, and R40 represents OH, -OR38, NHR39, or -NR38R39 X
J0-C-N-CH2-C .= C-CH2 -N-R 46
R44 VII 45
wherein R43 is alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to six carbon atoms, alkenyl of from two to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to six carbon atoms, alkynyl of from two to six carbon atoms, substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms,
Figure imgf000042_0001
wherein n is zero or an integer of one to eight and R47 and R are independently hydrogen, fluorine, chlorine, bromine, hydroxy, alkyl of from one to three carbon atoms, or alkoxy of from one to three carbon atoms, or alkoxy of from one to four carbon atoms, or
Figure imgf000042_0002
wherein R47 and R48 are as defined above; X is oxygen or sulfur; R44 is alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms alkenyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or
Figure imgf000043_0001
wherein n, R47 and R48 are as defined above R45 and R46 are each independently hydrogen, alkyl of from one to twenty carbon atoms, alkyl of from one to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to twenty carbon atoms, alkenyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to twenty carbon atoms, alkynyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to eight carbon atoms, phenyl, phenyl substituted with alkyl of from one to four carbon atoms, alkyl of from one to four carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkoxy of from one to four carbon atoms, chlorine, bromine, hydroxy, nitro or trifluoromethyl of R45 and R46 are taken together with the nitrogen atom to which they are attached to form a
Figure imgf000044_0001
wherein R49 is hydrogen, alkyl of from one to ten carbon atoms, alkyl of from one to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to ten carbon atoms, alkenyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms and n is as defined above,
Figure imgf000044_0002
wherein X is defined above or
Figure imgf000044_0003
wherein R50 is hydrogen or alkyl of from one to six carbon atoms,
Figure imgf000045_0001
wherein R51 is selected from the group consisting of
97/20561
-44-
Figure imgf000046_0001
R52 is hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms or aryl; n' is zero or an integer of one or two; X' is carbon or nitrogen; and ... represents a single or double bond with the proviso that when, ________ represents a double bond X' is nitrogen and when
_______ represents a single bond X' is CH2;
Figure imgf000047_0001
wherein R53 is selected from the group consisting
Figure imgf000047_0002
R54, R55, R56, and R57 are each independenty hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms, phenyl or phenyl substituted by one to four substituents selected from C1-C10 alkyl, alkoxy, C1-C10 halogen or trifluoromethyl; n' is an interger of one or two;
Figure imgf000047_0003
wherein X is oxygen, sulfur, or -N-R62, wherein R62 is hydrogen or alkyl of from one to ten carbon atoms; R58 is selected from the group consisting of
Figure imgf000048_0001
R5', R60, and R61 are each independently hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms or aryl; represents a single or double bond with the proviso that when represents a double bond R57 and R60 are absent;
Figure imgf000049_0001
wherein R63, R64, and R65 are each independently hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms, phenyl or phenyl substituted by one to four substituents selected from the group consisting of alkyl, alkoxy, thioalkoxy, halogen, and trifluoromethyl; R66 is hydrogen, hydroxy or alkoxy of from one to ten carbon atoms; and R67 is selected from the group consisting of
Figure imgf000049_0002
Figure imgf000049_0003
Figure imgf000049_0004
CH3
Figure imgf000050_0001
wherein
R69 is hydrogen and R67 is hydrogen, alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms, alkenyl of from three to six carbon atoms, substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or
R6a and R69 are taken together with the nitrogen atom to which they are attached to form a ring denoted by
Figure imgf000050_0002
wherein n' is zero or an integer from one to eight and R73 is hydrogen, alkyl of from one to ten carbon atoms, alkyl of from one to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to ten carbon atoms, alkenyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to ten carbon atoms or alkynyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms; R70 is hydrogen, alkyl of from one to six carbon atoms, alkyl of form one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms, alkenyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or R70 when taken together with R68 forms a ring denoted by
Figure imgf000051_0001
wherein n is an integer from one to three and R68 are as defined above;
R71 and R72 are each independently hydrogen, alkyl of from one to twenty carbon atoms, alkyl of from one to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to twenty carbon atoms, alkenyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to twenty carbon atoms, alkynyl of from three to twenty carbon atoms substituted with dydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to eight carbon atoms, phenyl, phenyl substituted with alkyl of from one to four carbon atoms, alkyl of from one to four carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkoxy of from one to four carbon atoms, chlorine, bromine, hydroxy, nitro or trifluoromethyl of R3 and R4 are taken together with the nitrogen atom to which they are attached to form a ring denoted by
Figure imgf000052_0001
wherein n' and R73 are ad defined above,
Figure imgf000052_0002
wherein X is defined above or
Figure imgf000052_0003
wherein R74 is hydrogen or alkyl of from one to six carbon atoms.
Figure imgf000052_0004
in which Z is a heterocyclic group
Figure imgf000053_0001
in which Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, or three nitrogen atoms, any amino nitrogen being substituted by a Cι-2 alkyl, cyclopropyl or propargyl group, and any ring carbon atom being optionally substituted by a group Ri; or a group
Figure imgf000053_0002
in which Ai, A2 and A3 complete a 5-membered aromatic ring and Ai is oxygen or sulphur, one of A2 and A3 is CR2 and the other is nitrogen or CR3, or A2 is oxygen or sulphur, one of A and A3 is CR2 and the other is CR3; and Ri, R2 and R3 are independently selected from hydrogen, halogen, CN, OR4, SR4, N(R )2, NHCOR4, NHCOOCH3, NHCOOC2H5, NHOR4, NHNH2, N02, COR4,
COR5, cyclopropyl, C2-5 straight chain alkenyl, C2-5 straight chain alkynyl or C1-5 straight chain alkyl optionally terminally substituted with OR4, (R4>2 SR4, CO2R4, CON(R4)2 or one, two or three halogen atoms, in which each R4 is independently hydrogen or C3.-3 alkyl and R5 is OR4, NH2 or NHR4; or in which Z is a group -C(R7)=NR6 in which R6 is a group OR8 where R8 is C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, a group OCOR9 where R9 is hydrogen or R8, or a group NHR10 or NRHR12 where Rχo, Rll and R12 are independently Ci- 2 alkyl and R7 is hydrogen or C1-4 alkyl, subject to the proviso that when Rβ is a group OCOR9 or NHRχo , 7 is C1-4 alkyl
Figure imgf000054_0001
in which one of X and Y represents hydrogen and the other represents Z, and Z" is a group
Figure imgf000054_0002
in which Q' represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises two or three nitrogen atoms, any amino nitrogen being substituted by a Cl-2 alkyl, cyclopropyl or propargyl group, r represents the integer of 2 or 3, s represents an integer of 1 or 2 and t represents 0, with the proviso that when Y is hydrogen s is 1;
Figure imgf000054_0003
wh€irein R75 represents
Figure imgf000055_0001
in which each of p and q independently represents an integer of 2 to 4, r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;
R76 is a group OR78, where R78 is Cι_4 alkenyl, C2-4 alkynyl, a group OCOR79 where R79 is hydrogen or R78, or a group NHR80 or NR81, R82, where R80, R81 and R82 are independently C1-2 alkyl; and R77 is hydrogen or Cι-4alkyl, subject to the proviso that when R76 is a group OCOR79 or a group NHR80, R77 is alkyl;
(3R, 4R) -3- (3-cyclopropyl-l, 2 , 4-oxadiazol-5-yl) -1- azabicyclo[2.2. lheptane; or a pharmaceutically acceptable salt or solvate thereof.
The term "low lipophilicity" refers to hydrogen, halogen, -CF3, -OR25, -NR25R26' "NHOR25- -NHNH2, -CN, COR8, or a substituted or unsubstituted, saturated or unsaturated hydrocarbon group; wherein R25 is hydrogen, Ci-Cβ alkyl, C2-6 alkenyl or C2-6 alkynyl; R26 is hydrogen, alkyl or -COCH3, and R27 represents -OR25 or -NR25R26-'
The term azacyclic or azabicyclic ring system is a non-aromatic ring system containing one nitrogen atom as the sole heteroatom. Sutably, the ring system contains from 4-10 ring atoms, preferably from 5-8 ring atoms. Preferably, the ring system contains a tertiary amino nitrogen atom in a ce.ged structure. The bicyclic systems may be fused, spiro, or birdged. Preferably, the nitrogen atom is at a bridgehead in a bicyclic system. Examples of such heteroatoms include the heteroatoms described in U.S. Patent 5,260,293, columns 2-3, which has been incorporated by reference.
The term "'927 azacyclic or '927 azabicyclic" refers to a non-aromatic ring system containing one nitrogen atom as the sole heteroatom. Suitably the ring contains from 4 to 10 ring atoms. Preferably from 5-8 ring atoms. The bicyclic systems may be fused, spiro or bridged. Examples of such heteroatoms include the bicyclic heteroatoms described in U.S. Patent 5,242,927 column 2, which has been incorporated by reference. The most preferred ' 927azabicyclic or ' 927azacyclic systems include pyrrolidine, 1, 2, 5, 6- etrahydropyridine, quinuclidine or 1- azabicyclo[2.2.l]heptane ring, optionally substituted with me-hyl or hydroxy. An especially preferred '927 azabicyclic ring is quinuclidine, which is substituted by hydrogen, methyl or hydroxy at any available atom.
Groups which are converted in vivo to an amino group on the compounds claimed herein for treating pain may be ascertained by administering the compound to a human or an animal and detecting, by conventional analytical techniques, the presence of the corresponding compound having an amino substituent in the urine of a human or animal. Examples of such groups include groups which are hydrolysable in vivo to an amino group, such as amido, urethan substituents. In particular a group of the formula -NH.Q whererin Q represents CHO, COR33 or C02R33, and R33 represents an optionally substituted hydrocarbon group. The term hydrocarbon group includes groups having up to 20 carbon atoms, suitably up to 10, and conveniently up to 8 carbon atoms. Suitable hydrocarbon groups include Cι_8 alkyl, C2-δalkenyl, C2- βalkynyl, C3_7cycloalkyl, C3_7cycloalkylCι_6alkyl, aryl and arylCi-galkyl.
Suitable R34 groups include the following:
Figure imgf000057_0001
wherein the broken line represents an otpional chemical bond; and R41 and R42 may be present at any position, including the point of attachment to the benzene ring, and independently represent hydrogen, Cι_4alkyl, F, Br, Cl, C1-4 alkoxy, hydroxy, carboxy, or Cι-4alkyoxycarbonyl or R41 and R42 together represent cabonyl. The nitrogen atom may be substituted by hydrogen or C1-4 alkyl.
The term "phenyl-Cι-C4 alkyl" designates an alkyl group which is substituted with a phenyl group. Preferred phenyl-alkyl groups include benzyl, 1- and 2-phenylethyl, 1-, 2-, 3-phenyla propyl and 1-methyl-1-phenylethyl . The phenyl group may be optionally be substituted with from 1-3 independently selected named substituents.
The term "form together with the nitrogen atom to which they are joined, a heterocyclic radical" means that a heterocyclic radical optionally containing another heteroatom, for example, S or 0. Such groups include, but are not limited to, piperidyl, piperazynyl, morpholinyl, and pyrrolidinyl.
The term "alkyl" refers to the number of carbon atoms indicated; however, when no number is specified, the term refers to C1-6 alkyl. The alkyl may be linear or branched unless specified. The term "halogen" refers to chloro, bromo, and fluoro substituents.
The term "alkynyl" has its accepted meaning; however, if the number of carbon atoms are unspecified, it refers to C2-10 alkynyl. The alkynyl group may be linear or branched unless specified.
The term alkoxy refers to Cι_4 alkoxy unless specified.
The term "analgesic dose", as used herein, represents an amount of compound necessary to prevent or treat a human susceptible to or suffering from pain following administration to such human. The active compounds are effective over a wide dosage range. For example, dosages per day will normally fall within the range of about 0.005 to about 500 mg/kg of body weight. In the treatment of adult humans, the range of about 0.05 to about 100 mg/kg, in single or divided doses, is preferred. However, it will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way. While the present compounds are preferably administered orally to humans susceptible to or suffering from anxiety, the compounds may also be administered by a variety of other routes such as the transdermal, parenterally, subcutaneous, intranasal, intramuscular and intravenous routes. Such formulations may be designed to provide delayed or controlled release using formulation techniques which are known in the art.
The term "NSAIDS", as used herein, represents a nonsteroidal anti-inflammatory drug which can be identified as such by the skilled artisan. For example, the Merck Manual, 16th Edition, Merck Research Laboratories (1990) pp 1308 - 1309 provide well known examples of NSAIDS. The term is intended to include, but is not limited to salicylates such as aspirin, indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac. Especially preferred NSAIDS include aspirin, ibuprofen, and naproxen. Alternative preferred NSAIDS are indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac.
Particularly preferred NSAIDS include aspirin and ibuprofen. The salicylates may include acetylsalicylic acid, sodium acetylsalicylic acid, calcium acetylsalicylic acid, salicylic acid, and sodium salicylate. An especially preferred NSAID is ibuprofen.
The term "acetaminophen", as used herein, shall have the art accepted meaning and refers to N-(4- Hydroxyphenyl)acetamide and 4 ' -hydroxyacetanilide. The compound is claimed in U.S. Patent No. 2,998,450 and is known to the skilled artisan.
The term "central alpha-adrenergic active compounds", as used herein, represents a compound having central alpha-adrenergic receptor activity. The most preferred central alpha-adrenergic active compound is clonidine or a pharmaceutically acceptable salt thereof having the chemical name: 2- (2, 6-dichlorophenylamino) -2- imidazoline.
Clonidine is known to be useful for treating hypertension. see Physicians' Desk Reference, 45th Ed. (1991) p. 673.
The term "opioid", as used herein, represents opioid analgesics and antagonists including natural opioid analgesics, synthetic opioid analgesics, opioid antagonists and opioid agonist-antagonists. Preferred an opioid compounds are selected from the group consisting of morphine, codeine, meperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, brompton's cocktail, naloxone, naltrexone, pentazocine, butorphanol, nabuphine, and buprenorphine. More preferred opioid compounds are selected from the group consisting of codeine, nabuphine, naloxone, and naltrexone. Preferred an opioid compounds are morphine, codeine, meperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, bro pton's cocktail, naloxone, naltrexone, pentazocine, butorphanol, nabuphine, and buprenorphine. Especially preferred opioid compounds are selected from the group consisting of hydromorphone, hydrocodone, meperidone, buprenorphine, butorphenol, nalbuphine, pentazocine, oxymorphine, oxycodone, l€ivorphanol, fentanyl, and alphaprodine. Particularly preferred opioid compounds are selected from the group consisting of propoxyphene, methadone, morphine, hydrocodone, hydromorphine, and codeine. The especially particularly preferred opioid compounds are selected from morphine and codeine.
As used herein, the phrase "one or more" most preferredly refers to one; however, two, three, or more may be used.
We have discovered that a group of compounds having muscarinic cholinergic activity can be particular useful for treating pain when used in combination with non-steroidal antiinflammatory agents (NSAIDS) . More specifically, the invention provides a method of treating pain in humans using a specified known compounds (collectively referred to herein as "selected muscarinic compounds") in combination with a NSAIDS to provide a synergistic effect. The Selected Muscarinic Compounds are believed to be active based on activity at muscarinic cholinergic receptors; however, the present invention is in no way limited by the mechanism of action.
There are many NSAIDS known in the literature and to the skilled artisan. We have discovered that a group of compounds having muscarinic cholinergic activity can be particular useful for treating pain when used in combination with acetaminophen. More specifically, the invention provides a method of treating pain in humans using a specified Selected Muscarinic Compounds in combination with acetaminophen to provide a synergistic effect.
Further, we have discovered that a group of compounds having muscarinic cholinergic activity can be particularly useful for treating pain when used in combination with central alpha-adrenergic active compounds. More specifically, the invention provides a method of treating pain in humans using Selected Muscarinic Compounds in combination with a central alpha-adrenergic active compound to provide a synergistic effect.
Oral combinations of aspirin with codeine or other narcotic analgesics are known to provide additive analgesic effects in man. The Pharmacological Basis of Therapeutics, 5th edition, Macmillan Publishing Co., 1975, pp 325-358. The present invention further envisions that one or more Selected Muscarinic Compounds may be used at one time in the composition of this invention to provide the desired analgesic effect.
In the composition of this invention a Selected Muscarinic Compound and NSAIDS compound are combined in a weight ratio of Compound to NSAIDS of from about 1 to about 1000.
A preferred composition is a weight ratio of Compound to NSAIDS of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A further preferred ratio may be from about 1 to about 10. A final preferred ratio may be from about 1 to about 3.
In the composition of this invention a Selected Muscarinic Compound and acetaminophen are combined in a weight ratio of Selected Muscarinic Compound to acetaminophen of from about 1 to about 1000. A preferred composition is a weight ratio of Selected Muscarinic Compound to acetaminophen of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A further preferred ratio may be from about 1 to about 10. A final preferred ratio may be from about 1 to about 3.
The Selected Muscarinic Compounds are effective over a wide dosage range,- however, it is desirable to administer a dosage that is as low as possible. The amount of NSAIDS present in the composition is adjusted as described above in ratio to the Selected Muscarinic Compound dosage. The amount of acetaminophen present in the composition is adjusted as described above in ratio to the Selected Muscarinic compound dosage.
In the composition of this invention a Selected Muscarinic Compound selected and one or more opioid compounds are combined in a weight ratio of Selected Muscarinic Compound to opioid compound of from about 1 to about 1000.
A preferred composition is a weight ratio of Selected Muscarinic Compound to opioid compound of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A further preferred ratio may be from about 1 to about 10. A final preferred ratio may be from about 1 to about 3.
The amount of opioid compound present in the composition is adjusted as described above in ratio to the Selected Muscarinic Compound dosage. However, for each composition claimed herein, it will be understood that the amount of the Selected Muscarinic Compound actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of Selected Muscarinic Compound to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way. While the present compounds are preferably administered orally to humans susceptible to or suffering from pain, the compounds may also be administered by a variety of other routes such as the transdermal, parenterally, subcutaneous, intranasal, intramuscular and intravenous routes. Such formulations may be designed to provide delayed or controlled release using formulation techniques which are known in the art.
Transdermal formulations containing the composition claimed herein most preferably deliver the active substances in an effective amount for from about three days to about seven days. However, for chronic pain such as arthritis or cancer pain, a transdermal delivery of from about three days to up to about two weeks is desirable. Alternatively, it may be preferred to deliver the claimed compositions transdermally in an effective amount for from about one day to about three days. As used herein the term "treating" includes prophylaxis of a physical and/or mental condition or amelioration or elimination of the developed physical and/or mental condition once it has been established or alleviation of the characteristic symptoms of such condition. The Selected Muscarinic Compounds employed in the invention are not believed to act via the
GABA/benzodiazepine, 5HT1A, or Dl receptor systems in humans. Rather, the activity of the present Selected Muscarinic Compounds as analgesic agents is believed to be based upon modulation of muscarinic cholinergic receptors. However, the mechanism by which the present compounds function is not necessarily the mechanism stated supra . , and the present invention is not limited by any mode of operation.
Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar pharmaceutically-acceptable inorganic or organic acid addition salts, and include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) which are known to the skilled artisan. The compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
The route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral or parenteral e.g. rectal, transdermal, depot, subcutaneous, intravenous, intramuscular or intranasal, the oral route being preferred. The dosage administered will, of course, vary depending on known factors such as the pharmacodynamic characteristics of the particular agent, and its mode and route of administration; age, health, and weight of the recipient; nature and extent of the symptoms, kind of concurrent treatment, frequency of treatment, and the effect desired. Usually, the daily dosage can be such that the active ingredient is administered at a daily dosage of from about 0.2 mg/kg to about 100 mg/kg of body weight SeLected Muscarinic Compound and from about 0.6 to about 200 mg/kg of NSAIDS.
Compositions suitable for internal administration contain from about one half (0.5) milligrams to about 600 milligrams of active ingredient per unit. In these pharmaceutical compositions, the active ingredient will ordinarily be present in an amount of from about 0.5% to about 95% by weight based on the total weight of the composition.
For compositions containing acetaminophen, usually, the daily dosage can be such that the active ingredient is administered at a daily dosage of from about 0.2 mg/kg to about 500 mg/kg of body weight Selected Muscarinic Compound and from about 0.6 to about 200 mg/kg of acetaminophen.
Typical compositions include a compound of Selected Muscarinic Compound and one or more NSAIDSs, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container for example in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring agents. The formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
Typical compositions include a Selected Muscarinic Compound and acetaminophen, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used, as described above. A preferred composition is a weight ratio of
Selected Muscarinic Compound to central alpha-adrenergic active compound of from about 1 to about 100. An especially preferred ratio is from about 1 to about 30. A further preferred ratio may be from about 1 to about 10. A final preferred ratio may be from about 1 to about 3.
The Selected Muscarinic Compounds are effective over a wide dosage range; however, it is desirable to administer a dosage that is as low as possible. The amount of central alpha-adrenergic active compound present in the composition is adjusted as described above in ratio to the Selected Muscarinic Compound dosage.
Usually, the daily dosage can be such that the active ingredient is administered at a daily dosage of from about 0.2 mg/kg to about 500 mg/kg of body weight Selected Muscarinic ompound and from about 0.6 to about 200 mg/kg of central alpha-adrenergic active compound.
Typical compositions include a Selected Muscarinic Compound and one or more central alpha- adrenergic active compounds, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used.
The pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compounds. For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.
Generally, the compositions of this invention are dispensed in unit form comprising from about 0.1 to about 300 mg in a pharmaceutically acceptable carrier per unit dosage.
The compositions of this invention may be suitable for administration to an animal. Such animals include both domestic animals, for example livestock, laboratory animals, and household pets, and non-domestic animals such as wildlife. More preferredly, the animal is a vertebrate. Most preferredly, a composition of this invention shall be administered to a mammal. It is especially preferred that the animal is a domestic mammal or a human. The most preferred mammal is a human. For such domestic animal purposes, a composition of this invention may be administered as a feed additive.
The following models and assays are useful for illustrating the effectiveness of the compositions claimed herein.
Nociceptive pain model:
Acetic acid-induced writhing: A standard procedure for detecting and comparing the analgesic activity of different classes of analgesic drugs for which there is a good correlation with human analgesic activity is the prevention o acetic acid-induced writhing in mice. Mice, are subcutaneously administered various doses of the claimed composition and are injected injected intraperitoneally with acetic acid (0.5% solution, 10 ml/kg) 5 min prior to a designated observation period. For scoring purposes a
"writhe" is indicated by whole body stretching or contraction of the abdomen during the observation period beginning 5 min after receiving the acetic acid. Inhibition of writhing behavior is demonstrative of analgesic activity. See, Haubrich, D.R., Ward, S.J., Baizman, E., Bell, M.R. , Bradford, J., Ferrari, R., Miller, M. , Perrone, M. , Pierson, A.K., Saelens, J.K. and Luttinger, D. : Pharmacology of pravadoline: a new analgesic agent. The Journal of Pharmacology and Experimental Therapeutics 255 (1990) 511-522.
Neuropathic pain model:
Sciatic nerve ligation model: Rats are anesthetized and a nerve ligation procedure performed. The common sciatic nerve is exposed and 4 ligatures tied loosely around it with about 1 mm spacing. One day to 10 weeks after surgery, the nociceptive testing is performed. Responses to noxious heat are determined by placing the rats in a chamber with a clear glass floor and aiming at the plantar surface of the affected foot a radiant heat source from beneath the floor. Increased latency to withdraw the hindpaw is demonstrative of analgesic activity. Responses to normally innocuous mechanical stimuli is determined by placing the rats in a chamber with a screen floor and stimulating the plantar surface of the hind paw wit.h graduated von Frey hairs which are calibrated by the gre.ms of force required to bend them. Rats with sciatic nerve ligation respond to lower grams of mechanical stimulation by reflexive withdrawal of the foot than uncperated rats. This response to stimuli which are normally innocuous is termed allodynia. Increases in the grams of mechanical force required to produce foot withdrawal is demonstrative of antiallodynic activity. See, Bennett, G.J. and Xie, Y.-K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33 (1988) 87-107. See also, Lee, Y.-W., Chaplan, S.R. and Yaksh, T.L.: Systemic and supraspinal, but not spinal, opiates suppress allodynia in a rat neuropathic pain model. Neuroci Lett 186 (1995) 111-114. Formalin paw test: Rats are anesthetized and when there is a loss of spontaneous movement the rats are injected subcutaneously in the dorsal surface of the hindpaw with 50 ul of 5% formalin solution using a 30 gauge needle. Rats are then individually placed in an open Plexiglas chamber for observation, and within a maximum interval of 1 to 2 min, the animal displays recovery from anesthesia with spontaneous activity and normal motor function. Pain behavior is quantified by periodically counting the incidents of spontaneous flinching/shaking of the injected paw. The flinches are counted for 1-min periods at 1- to 2-, 5- to 6- and 5min intervals during the interval from 10 to 60 min. Inhibition of the pain behavior is demonstrative of an analgesic activity.
See, Malmberg, A.B. and Yaksh, T.L. : Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat. The Journal of Pharmacology and Experimental Therapeutics 263 (1992) 136-146.
Inflammatory pain model:
Brewer's yeast-induced hyperalgesia (Randall-Selitto
Test): To assess nociceptive threshold in rats, ascending pressure is applied gradually to the paw with a motor driven weight of a Ugo Basile Analgesy Meter. Rats respond to the pressure by either pulling free of the device, struggling or vocalizing. Hyperalgesia is induced by a hind paw subplantar injection of 0.1 ml of 1% suspension of brewer's yeast in 0.9% saline. The composition of this invention is administered at varying times ( 0 - 4 hr) after injection of brewer's yeast and pressure threshold for the inflamed paw again determined at varying times. Increases in the pressure which produces a behavioral response is demonstrative of analgesic activity.
See, Haubrich, D.R., Ward, S.J., Baizman, E. , Bell, M.R., Bradford, J., Ferrari, R., Miller, M. , Perrone, M. , Pierson, A.K. , Saelens, J.K. and Luttinger, D. : Pharmacology of pravadoline: a new analgesic agent. The Journal of Pharmacology and Experimental Therapeutics 255 (1990) 511-522.
Utility Test Methods The unexpectedly enhanced analgesic activity of the composition of the invention is evidenced by tests intially conducted on mice. Male mice are fasted for 16-22 hours and weighed. Mice weighing from about 18-22 grams at the time of testing are used for the following studies. All mice are dosed sequentially by the oral route with suspensions of a composition of this invention. Doses are coded using a code unknown to the observer. A stock suspension of the test composition is prepared by mixing the active ingredients with about 40 mL of an aqueous vehicle containing about 2% Tween 80 (R) , a pharmacological dispersant and containing 100% polysorbate 80, and 1% by weight Methocel (R) MC powder, and containing 100% methylcellulose, in distilled water. The mixture may be sonicated for about 10 to about 15 seconds using an ultrasound sytem. All dosing suspensions are prepared by dilution of the stock suspension with Methocel/Tween 80. All suspensions are used within two hours of preparation.
MQvse writhing est
An accepted standard for detecting and comparing the analgesic activity of different classes of analgesic compounds for which there is a good correlation with human analgesic activity is the prevention of phenyl-p- benzoquinone induced writhing in mice. [H. Blumberg et al. Proc. Soc. Exp. biol. Med., 118, 763-766 (1965)] . Mice, treated with various doses of Selected Muscarinic Compound, composition or vehicle are injected intraperitoneally with a standard challenge dose of phenyl- p-benzoquinone 5 minutes prior to a designated observation period. The pheyl-p-benzoquinone is prepared as about 0.1 mg/ml solution in about 5% by volume of ethanol in water. The writhing dose is 1.25 mg/kg injected at a volume of about 0.25ml/10g. For scoring purposes a "writhe" is indicated by whole body stretching or contracting of the abdomen during an observation period beginning about five minutes after the phenyl-p-benzoquinone dose.
All ED50 values and their 95% confidence limits are determined using accepted numerical methods. For example, see W.F. Thompson, Bacteriological Rev.. 11, 115- 145 (1947) . The interaction of the dosages on phenyl-p- benzoquinone induced writhing in mice is demonstrated by the Loewe isobologram (S. Loewe, Pharm. Rev. 9, 237-242 (1957) .
The solid line connecting the ED50 dosages of Selected Muscarinic Compound (alone) and Synergistic
Analgesic as claimed herein (alone) represents the "ED50 addition line" which indicates the expected location of the ED50'ε for Selected Muscarinic Compound and classical analagesic combinations if simple additivity were to describe their combined effects. The 95% confidence range for the ED50 addition line is shown by the area between the broken lines above and below the ED50 addition line.
According to Loewe' s isobolic theory, if the analgesic effects are simply additive to one another, then the expected location of the ED50's of the Selected
Muscarinic Compound and Synergistic Analgesic component of each fixed dosage ratio would be contained within or overlap the region of the ED50 addition line. Combination ED50's located significantly below the ED50 addition line would represent unexpectedly enhanced analgesic activity and combination ED50's located above the line would represent unexpected diminished analgesic effect. One method to establish the significance of such unexpected enhanced or diminished activity is to calculate the best fitting polynomial regression line to the observed ED50's using standard mathematical techniques. Such experiments demonstrate that compositions comprised of a Selected Muscarinic Compound and one or more Synergistic Analgesics provides a statistically significant synergistic analgesic effect.
Preferred compounds for use in treating pain include:
OR, 4R) -3- (3-cyclopropyl-1,2, 4-oxadiazol-5-yl) -1- azabicyclo[2.2.lheptane and compounds of Formulae IV, V, v::ιι, IX, XIII, XIV, and XV; or a pharmaceutically acceptable salt thereof. Especially preferred compounds include the following: compounds of Formulae XIII, XIV, and XV.
Examples of preferred compounds include, but are not limited to, 3- [2- (δ-hydroxypyrazin)yl] -1- azabicyclo[2.2.2]octane, 3- (2-pyrazinyl) -1- azabicyclo [2.2.1]heptane, 6- (2-pyrazinyl) -1- azabicyclo[3.2.1]octane, 6- (2-pyrazinyl) -1- azabicyclo[3.2.l]octan-6-ol, 3-fluoro-3- (2-pyrazinyl) -1- azabicyclo[2.2.1]heptane, 1-methyl-3- (2- pyrazinyl)pyrrolidine, 3- [2- (3-methylpyrazin)yl] -1- azabicyclo[2.2.2]octan-3-ol, 3- [2- (3 , 6-dimethylpyrazin)yl] -1- azabicyclo[2.2.1]heptane, 3- [2- (6-allyloxypyrazin)yl] -1- azabicyclo[2.2.1]heptane,3- [2- (6-methoxypyrazin)yl] -1- azabicyclo[2.2.2]octane, 3- [2- (6-chloropyrazin)yl] -1,2,5,6- tetrahydropyridine, 3- [5- (3-octanyloxycarbonylamino-l , 2, 4- oxadiazol) -yl] -1-azabicyclo[2.2.1] eptane, 3-[5- (3- cyclohexylcarbonylamino-1, 2, 3-oxadiazol) -yl]quinuclidine, 3- [5- (3- (1- (3-n-pentyloxycarbonyl) -1-ethoxycarbonylamino) - 1,2, 4-oxadiazol) -yl] uinuclidine, 3- [5- (3-octanoylamino- 1,2, 4-oxadiazol) -yl]quinuclidine, 3- [ (l-methyl-lH-imidazol-5- yl)methyl] 1,2, 4-oxadiazol-5 (4H) -one, 4-methyl-3- [ (1-methyl- lH-imidazol-4-yl) -methyl] 1,2, 4-oxadiazol-5 (4H) -one, 4-ethyl- 3 [ (l-methyl-lH-imidazol-4-yl) -methyl] -1,2 , 4-oxadiazol-5 (4H) - one, N- [4- (hexahydro-lH-azaepin-1-yl) -2-butynyl] -N,N-dimethyl urea, N- [4-1-pyrrolidinyl) -2-butynyl] -urea, 5-acetyl-l- azabicyclo [3.1.1]heptane, 1-azabicyclo[3.1.1]hept-5- ylcarboxaldehyde, 3- (2-methyltetrazol-5-yl) -1- azabicyclo[2.2.1]heptane, 3- (2-methyl-l,2, 3-triazol-4-yl) -1- azabicyclo- [2.2.2]octane, 3- (3-cyclopropyl-l, 2, 4-oxadiazol-5- yl) -1-azabicyclo[2.2.l]heptane, and a pharmaceutically acceptable salt or solvate thereof.

Claims

We Claim:
1. A composition for treating pain comprising an analgesic dose of a Compound selected from the group consisting of:
Figure imgf000074_0001
wherein R1 is hydrogen, Ci-Cβ alkyl or phenyl-Cι-C4 alkyl, in which the phenyl group may be substituted with halogen, C1-C4 alkyl or C1-C4 alkoxy;
R2 is Ci-Cgalkyl, C3-C6 alkenyl, C3-C6 alkynyl, branched or unbranched with 1-6 carbon atoms inclusive, which group may be optionally substituted with fluoro, hydroxy or phenyl optionally substituted with fluoro, trifluoromethyl, lower alkyl, hydroxy, or lower alkoxy; R3 and R4 are independently hydrogen, Cι~Cβ alkyl, C3-C6 cycloalkyl, phenyl optionally substituted with halogen trifluroromethyl, C1-C4 alkyl, hydroxy, or C -C4 alkoxy, or phenyl-C1-C4 alkyl, in which the phenyl group may be substituted with halogen, C1-C4 alkyl or C1-C4 alkoxy;
Figure imgf000074_0002
in which R5 represents the radical
Figure imgf000074_0003
in which R6 at any position on the benzene ring represents linear, branched or cyclic Ci-Cβ alkyl, C2-C8 alkenyl or C2- C8 alkynyl or the radical
N-R»
in which R7 and R8 which may be identical or different represent hydrogen, linear Ci-Cβ alkyl, C2-C8 alkenyl or C2- C8 alkynyl or form together with the nitrogen atom to which they are attached a carbonaceous hetercyclic radical optionally containing another heteroatom, or the radical OR9, R9 representing hydrogen, linear, branched or cyclic Ci-Cβ alkyl, C2-C8 alkenyl or C2-C8 alkynyl or aryl containing up to 14 carbon atoms, or the radical SR10 or S(0)Rn, R10 and R11 represent linear, branched or cyclic Ci-Cs alkyl, C2-C8 alkenyl or C2-C8 alkynyl, or R5 represents naphthyl optionally substituted with R6' - R6' being defined above for R6;
Figure imgf000075_0001
in which R12 represents the radical
Figure imgf000075_0002
in which R13 at any position on the benzene ring represents linear, branched or cyclic Ci-Cβ alkyl, C2-C8 alkenyl or C2- Cδ alkynyl or the radical
Figure imgf000075_0003
in which R14 and R15 which may be identical or different represent hydrogen, linear Ci-Cβ alkyl, C2-C8 alkenyl or C2- Cβ alkynyl or form together with the nitrogen atom to which they are attached a carbonaceous hetercyclic radical optionally containing another heteroatom, or the radical or
NO2, or OR12', R1 ' representing hydrogen, linear, branched or cyclic Ci-Cβ alkyl, C2-C8 alkenyl or C2-C8 alkynyl or aryl containing up to 14 carbon atoms, or the radical SR16 or S(0)R17, R16 and R17 represent linear, branched or cyclic Ci- Cs alkyl, C2-C8 alkenyl or C2-C8 alkynyl, or R12 represents naphthyl optionally substituted with R13'- R13' being defined above for R13;
Figure imgf000076_0001
wherein, one of R18, R19, and R20 represents nitrogen and the remainder represent carbon atoms; substituted on one of the ring carbon atoms with a R24 substituent represented by a non¬ aromatic azacyclic or azabicyclic ring system and independently substituted on each of the other ring carbon atoms with R23, R21, or R22 substituent of low lipophilicity or a hydrocarbon having a maximum of 20 carbon atoms;
Figure imgf000076_0002
wherein one of R28, R29 or R30 is an oxygen atom and the other two are nitrogen atoms, and the dotted circle represents aromaticity (two double bonds) thus forming a 1, 3, 4-oxadiazole or 1, 2, 4-oxadiazole nucleus; R31 represents a non-aromatic '927azacycle or ' 927azabicyclic ring system; and R32 represents a substituent which is convertable in vivo to an amino group;
Figure imgf000077_0001
wherein R34 represents a non-aromatic; non-fused 1- azabicyclic ring system; and R35, R36, and R37 independently represent hydrogen, F, Cl, Br, -CF3, -OR38, -NR38R39, -NHOR38, -NHNH , -CN, COR40, or a substituted or unsubstituted, saturated or unsaturated hydrocarbon group, provided that at least one of R35, R36, and R37 is other than hydrogen or a hydrocarbon group, or R35 and R36 or R37 taken together form a Cι_6alkylenedioxy ring, wherein R38 is Ci-galkyl, C2-βalkenyl or C2-6alkynyl, R39 is hydrogen, Cι-6 alkyl,or -COCH3, and R40 represents OH, -OR38, NHR39, or -NR38R39
Figure imgf000077_0002
wherein R43 is alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to six carbon atoms, alkenyl of from two to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to six carbon atoms, alkynyl of from two to six carbon atoms, substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms,
Figure imgf000078_0001
wherein n is zero or an integer of one to eight and R47 and R48 are independently hydrogen, fluorine, chlorine, bromine, hydroxy, alkyl of from one to three carbon atoms, or alkoxy of from one to three carbon atoms, or alkoxy of from one to four carbon atoms, or
Figure imgf000078_0002
wherein R47 and R48 are as defined above;
X is oxygen or sulfur; R44 is alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms alkenyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or
Figure imgf000079_0001
wherein n, R47 and R48 are as defined above R45 and R46 are each independently hydrogen, alkyl of from one to twenty carbon atoms, alkyl of from one to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to twenty carbon atoms, alkenyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to twenty carbon atoms, alkynyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to eight carbon atoms, phenyl, phenyl substituted with alkyl of from one to four carbon atoms, alkyl of from one to four carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkoxy of from one to four carbon atoms, chlorine, bromine, hydroxy, nitro or trifluoromethyl of R45 and R46 are taken together with the nitrogen atom to which they are attached to form a ring denoted by
Figure imgf000079_0002
wherein R49 is hydrogen, alkyl of from one to ten carbon atoms, alkyl of from one to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to ten carbon atoms, alkenyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms and n is as defined above,
f ΓΛ y.
wherein X is defined above or
Figure imgf000080_0001
wherem R50 is hydrogen or alkyl of from one to six carbon atoms,
Figure imgf000080_0002
wherein R51 is selected from the group consisting of
Figure imgf000081_0001
R52 is hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms or aryl; n' is zero or an integer of one or two; X' is carbon or nitrogen; and ... represents a single or double bond with the proviso that when, ^___^. represents a double bond X' is nitrogen and when ________ represents a single bond X' is CH2;
Figure imgf000082_0001
wherein R53 is selected from the group consisting
Figure imgf000082_0002
R'54, R55, R56, and R57 are each independenty hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms, phenyl or phenyl substituted by one to four substituents selected from C1-C10 alkyl, alkoxy, C1-C10 halogen or trifluoromethyl; n' is an interger of one or two;
Figure imgf000082_0003
wherein X is oxygen, sulfur, or -N-R62, wherein R62 is hydrogen or alkyl of from one to ten carbon atoms; R58 is selected from the group consisting of
Figure imgf000083_0001
R59, R60, and R61 are each independently hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms or aryl; represents a single or double bond with the proviso that when represents a double bond R57 and R60 are absent; \ 2 -
Figure imgf000084_0001
wherein R63, R64, and R65 are each independently hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms, phenyl or phenyl substituted by one to four substituents selected from the group consisting of alkyl, alkoxy, thioalkoxy, halogen, and trifluoromethyl; R66 is hydrogen, hydroxy or alkoxy of from one to ten carbon atoms; and R67 is selected from the group consisting of
Figure imgf000084_0002
Figure imgf000084_0003
Figure imgf000084_0004
CH3
Figure imgf000085_0001
wherein
R69 is hydrogen and R67 is hydrogen, alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms, alkenyl of from three to six carbon atoms, substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or
R68 and R69 are taken together with the nitrogen atom to which they are attached to form a ring denoted by
Figure imgf000085_0002
wherein n' is zero or an integer from one to eight and R73 is hydrogen, alkyl of from one to ten carbon atoms, alkyl of from one to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to ten carbon atoms, alkenyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to ten carbon atoms or alkynyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms; R70 is hydrogen, alkyl of from one to six carbon atoms, alkyl of form one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms, alkenyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or R70 when taken together with R68 forms a ring denoted by
Figure imgf000086_0001
wherein n is an integer from one to three and R68 are as defined above;
R71 and R72 are each independently hydrogen, alkyl of from one to twenty carbon atoms, alkyl of from one to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to twenty carbon atoms, alkenyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to twenty carbon atoms, alkynyl of from three to twenty carbon atoms substituted with dydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to eight carbon atoms, phenyl, phenyl substituted with alkyl of from one to four carbon atoms, alkyl of from one to four carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkoxy of from one to four carbon atoms, chlorine, bromine, hydroxy, nitro or trifluoromethyl of R3 and R4 are taken together with the nitrogen atom to which they are attached to form a ring denoted by
Figure imgf000087_0001
wherein n' and R73 are ad defined above,
Figure imgf000087_0002
—N
wherein X is defined above or
Figure imgf000087_0003
wherein R74 is hydrogen or alkyl of from one to six carbon atoms,
Figure imgf000087_0004
in which Z is a heterocyclic group
Figure imgf000088_0001
in which Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, or three nitrogen atoms, any amino nitrogen being substituted by a Cι-2 alkyl, cyclopropyl or propargyl group, and any ring carbon atom being optionally substituted by a group Ri; or a group
Figure imgf000088_0002
in which Ai, A2 and A3 complete a 5-membered aromatic ring and Ai is oxygen or sulphur, one of A2 and A3 is CR2 and the other is nitrogen or CR3, or A2 is oxygen or sulphur, one of A and A3 is CR2 and the other is CR3; and Ri, R2 and R3 are independently selected from hydrogen, halogen, CN, OR4, SR4, N(R4)2, NHCOR4, NHCOOCH3, NHCOOC2H5, NHOR4, NHNH2, N02, COR4, COR5, cyclopropyl, C2-5 straight chain alkenyl, C2-5 straight chain alkynyl or C1-5 straight chain alkyl optionally terminally substituted with OR4, N(R4)2 SR4, CO2R4, CON(R4)2 or one, two or three halogen atoms, in which each R4 is independently hydrogen or C1-3 alkyl and R5 is OR4, NH2 or NHR4; or in which Z is a group -C(R7)=NR6 in which Rζ is a group OR8 , where R8 is C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, a group OCORg where Rg is hydrogen or Rs, or a group NHR10 or R11R12 where Rio, Rll and R12 are independently Ci- 2 alkyl and R7 is hydrogen or C1-4 alkyl, subject to the proviso that when R6 is a group OCOR9 or NHR10, R7 is C1-4 alkyl
Figure imgf000089_0001
in which one of X and Y represents hydrogen and the other represents Z, and Z' is a group
Figure imgf000089_0002
in which Q' represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises two or three nitrogen atoms, any amino nitrogen being substituted by a Cl-2 alkyl, cyclopropyl or propargyl group, r represents the integer of 2 or 3, s represents an integer of 1 or 2 and t represents 0, with the proviso that when Y is hydrogen s is 1;
Figure imgf000089_0003
wherein R75 represents
Figure imgf000090_0001
in which each of p and q independently represents an integer of 2 to 4, r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;
R76 is a group OR78, where R78 is C1-.4 alkenyl, C2-4 alkynyl, a group OCOR79 where R79 is hydrogen or R78, or a group NHR80 or NR81, R82, where R80, R81 and R82 are independently C1-2 alkyl; and R77 is hydrogen or Cι-4alkyl, subject to the proviso that when R76 is a group OCOR79 or a group NHR80, R77 is alkyl;
(3R,4R) -3- (3-cyclopropyl-l,2,4-oxadiazol-5-yl)-1- azabicyclo[2.2.lheptane; or a pharmaceutically acceptable salt or solvate thereof; and one or more Synergistic Analgesics in a weight ratio of Compound to Synergistic Analgesic of from about 1 to about 1000.
2. A composition as claimed by Claim 1 wherein the Compound is selected from the group consisting of Formula
IV, V, VIII, IX, XIII, XIV, and XV; or a pharmaceutically acceptable salt or solvate thereof.
3. A composition as claimed by Claim 1 wherein the Synergistic Analgesic is a nonsteroidal anti-inflammatory drug. 4. A composition as claimed by Claim 3 wherein the nonsteroidal anti-inflammatory drug is selected from the group consisting of indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac.
5. A composition as claimed by Claim 3 wherein the nonsteroidal anti-inflammatory drug is ibuprofen.
6. A composition as claimed by Claim 3 wherein the Compound is selected from the group consisting of Formula IV, V, VIII, IX, XIII, XIV, and XV; or a pharmaceutically acceptable salt or solvate thereof.
7. A composition as claimed by Claim 1 wherein the Synergistic Analgesic is an opioid.
8. A composition as claimed by Claim 7 wherein the Compound is selected from the group consisting of Formula IV,
V, VIII, IX, XIII, XIV, and XV; or a pharmaceutically acceptable salt or solvate thereof.
9. A composition as claimed by Claim 8 wherein the Compound is selected from the group consisting of l-azabicyclo[2.2.2]oct-3-yl cyclopropyl ketone, 1-azabicyclo[2.2.l]hept-3-yl cyclopropyl ketone, 3-oxo-3- (1-azabicyclo[2.2.1]hept-3-yl)propionitrile, l-azabicyclo[2.2.2]oct-3-yl-N-methoxycarboxamide, 1-azabicyclo[3.2.1] oct-5-yl-N-methoxycarboxamide, 1-azabicyclo[2.2. l]hept-3-yl-N-methoxycarboxamide,
(methoxyimino) - (1-azabicyclo [2.2.2]oct-3-yl)acetonitrile, oximino- (1-azabicyclo[2.2.2] oct-3-yl) acetonitrile, and l-azabicyclo[2.2.2]oct-3-ylidecyanoacetic acid; or a pharmaceutically acceptable salt thereof.
10. A composition as claimed by Claim 8 wherein the opioid is selected from the group consisting of morphine, codeine, meperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, bro pton' s cocktail, naloxone, naltrexone, pentazocine, butorphanol, nabuphine, and buprenorphine. 11. A composition as claimed by Claim 8 wherein the opioid is selected from the group consisting of hydromorphone, hydrocodone, meperidone, buprenorphine, butorphenol, nalbuphine, pentazocine, oxymorphine, oxycodone, levorphanol, fentanyl, and alphaprodine.
12. A composition as claimed by Claim 8 wherein the opioid is selected from the group consisting of propoxyphene, methadone, hydrocodone, hydromorphine, and codeine. 13. A composition as claimed by Claim 1 wherein the Compound is selected from the group consisting of Formula I, II, and III; or a pharmaceutically acceptable salt or solvate thereof.
1 . A composition as claimed by Claim 1 wherein the Compound is selected from the group consisting of Formula XIV and XV; or a pharmaceutically acceptable salt or solvate thereof.
15. A composition as claimed by Claim 14 wherein the Compound is selected from the group consisting of 1-azabicyclo[2.2.2]oct-3-yl cyclopropyl ketone, l-azabicyclo[2.2. l]hept-3-yl cyclopropyl ketone, 3-oxo-3- (1-azabicyclo[2.2.1]hept-3-yl)propionitrile, 1-azabicyclo[2.2.2]oct-3-yl-N-methoxycarboxamide, 1-azabicyclo [3.2.1]oct-5-yl-N-methoxycarboxamide, 1-azabicyclo[2.2.l]hept-3-yl-N-methoxycarboxamide,
(m thoxyimino) - (1-azabicyclo [2.2.2]oct-3-yl)acetonitrile, oximino- (1-azabicyclo[2.2.2]oct-3-yl)acetonitrile, and l-azabicyclo[2.2.2]oct-3-ylidecyanoacetic acid; or a pharmaceutically acceptable salt thereof. 16. A composition as claimed by Claim 1 wherein the Synergistic Analgesic is acetaminophen.
17. A composition as claimed by Claim 15 wherein the Compound is selected from the group consisting of Formula IV, V, VIII, IX, XIII, XIV, and XV; or a pharmaceutically acceptable salt or solvate thereof.
18. A composition as claimed by Claim 17 wherein the Compound is selected from the group consisting of 1-azabicyclo[2.2.2]oct-3-yl cyclopropyl ketone, l-azabicyclo[2.2.l]hept-3-yl cyclopropyl ketone, 3-oxo-3- (1-azabicyclo[2.2.1]hept-3-yl)propionitrile, 1-azabicyclo[2.2.2]oct-3-yl-N-methoxycarboxamide, 1-azabicyclo[3.2.1]oct-5-yl-N-methoxycarboxamide, 1-azabicyclo[2.2.1]hept-3-yl-N-methoxycarboxamide, (methoxyimino) - (1-azabicyclo[2.2.2]oct-3-yl)acetonitrile, oximino-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile, and l-azabicyclo[2.2.2]oct-3-ylidecyanoacetic acid; or a pharmaceutically acceptable salt thereof.
19. A composition as claimed by Claim 1 wherein the Synergistic Analgesic is an alpha-adrenergic compound.
20. A composition as claimed by Claim 19 wherein the Compound is selected from the group consisting of Formula IV, V, VIII, IX, XIII, XIV, and XV; or a pharmaceutically acceptable salt or solvate thereof.
21. A composition as claimed by Claim 20 wherein the Compound is selected from the group consisting of l-azabicyclo[2.2.2]oct-3-yl cyclopropyl ketone, l-azabicyclo[2.2.l]hept-3-yl cyclopropyl ketone,
3-oxo-3- (1-azabicyclo[2.2.1]hept-3-yl)propionitrile, 1-azabicyclo[2.2.2]oct-3-yl-N-methoxycarboxamide, 1-azabicyclo[3.2.1]oct-5-yl-N-methoxycarboxamide, 1-azabicyclo[2.2.1]hept-3-yl-N-methoxycarboxamide, (methoxyimino) - (1-azabicyclo[2.2.2]oct-3-yl)acetonitrile, oximino-(1-azabicyclo[2.2.2]oct-3-y1)acetonitrile, and l-azabicyclo[2.2.2]oct-3-ylidecyanoacetic acid; or a pharmaceutically acceptable salt thereof.
22. A method for treating pain comprising administering an analgesic dose of a composition comprising a compound a Compound selected from the group consisting of:
Figure imgf000094_0001
wherein R1 is hydrogen, Ci-Cβ alkyl or phenyl-Cι~C4 alkyl, in which the phenyl group may be substituted with halogen, C1-C4 alkyl or C1-C4 alkoxy;
R2 is C -C6alkyl, C3-C6 alkenyl, C3-C6 alkynyl, branched or unbranched with 1-6 carbon atoms inclusive, which group may be optionally substituted with fluoro, hydroxy or phenyl optionally substituted with fluoro, trifluoromethyl, lower alkyl, hydroxy, or lower alkoxy;
R3 and R4 are independently hydrogen, C -Cts alkyl, C3-C6 cycloalkyl, phenyl optionally substituted with halogen trifluroromethyl, C1-C4 alkyl, hydroxy, or C1-C4 alkoxy, or phenyl-Cι~C4 alkyl, in which the phenyl group may be substituted with halogen, C1-C4 alkyl or C1-C4 alkoxy;
Figure imgf000094_0002
in which R5 represents the radical
Figure imgf000094_0003
in which R6 at any position on the benzene ring represents linear, branched or cyclic C -Cs alkyl, C2-C8 alkenyl or C2- CΘ alkynyl or the radical N-R»
in which R7 and R8 which may be identical or different represent hydrogen, linear Ci-Cβ alkyl, C2-C8 alkenyl or C2- Cβ alkynyl or form together with the nitrogen atom to which they are attached a carbonaceous hetercyclic radical optionally containing another heteroatom, or the radical OR9, R9 representing hydrogen, linear, branched or cyclic Ci-Cs alkyl, C2-C8 alkenyl or C2-C8 alkynyl or aryl containing up to 14 carbon atoms, or the radical SR10 or S(0)R , R10 and R11 represent linear, branched or cyclic C -Cs alkyl, C2-C8 alkenyl or C2-C8 alkynyl, or R5 represents naphthyl optionally substituted with R6'< R6' being defined above for R6;
Figure imgf000095_0001
in which R12 represents the radical
in which R13 at any position on the benzene ring represents linear, branched or cyclic Ci-Cs alkyl, C2-C8 alkenyl or C2- Cδ alkynyl or the radical
,14
N
-R15
in which R14 and R15 which may be identical or different represent hydrogen, linear Ci-Cs alkyl, C2-C8 alkenyl or C2- Q alkynyl or form together with the nitrogen atom to which t ey are attached a carbonaceous hetercyclic radical optionally containing another heteroatom, or the radical or NO2, or OR12', R12' representing hydrogen, linear, branched or cyclic Ci-Cβ alkyl, C2-C8 alkenyl or C2-C8 alkynyl or aryl containing up to 14 carbon atoms, or the radical SR16 or S(0)R17, R16 and R17 represent linear, branched or cyclic Cι~ C(i alkyl, C2-C8 alkenyl or C2-C8 alkynyl, or R12 represents naphthyl optionally substituted with R13 ' > R13' being defined above for R13;
Figure imgf000096_0001
wherein, one of R18, R19, and R20 represents nitrogen and the remainder represent carbon atoms; substituted on one of the ring carbon atoms with a R24 substituent represented by a non¬ aromatic azacyclic or azabicyclic ring system and independently substituted on each of the other ring carbon atoms with R23, R21, or R22 substituent of low lipophilicity or a hydrocarbon having a maximum of 20 carbon atoms;
Figure imgf000096_0002
wherein one of R28, R29 or R30 is an oxygen atom and the other two are nitrogen atoms, and the dotted circle represents aromaticity (two double bonds) thus forming a
1, , 4-oxadiazole or 1, 2, 4-oxadiazole nucleus; R31 represents a non-aromatic '927azacycle or ' 927azabicyclic ring system; and R32 represents a substituent which is convertable in vivo to an amino group;
Figure imgf000097_0001
wherein R34 represents a non-aromatic; non-fused 1- azabicyclic ring system; and
R35, R36, and R37 independently represent hydrogen, F, Cl , Br, -CF3, -OR38, -NR38R39, -NHOR38, -NHNH2 , -CN, COR40, or a substituted or unsubstituted, saturated or unsaturated hydrocarbon group, provided that at least one of R35, R36, and R37 is other than hydrogen or a hydrocarbon group, or R35 and R36 or R37 taken together form a Ci-galkylenedioxy ring, wherein R38 is Cι_6alkyl, C2-ealkenyl or C2-6alkynyl, R39 is hydrogen, Cι_6 alkyl, or -COCH3, and R40 represents OH, -OR38, NHR39, or -NR38R39
Figure imgf000097_0002
wherein R43 is alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to six carbon atoms, alkenyl of from two to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to six carbon atoms, alkynyl of from two to six carbon atoms, substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms,
Figure imgf000098_0001
wherein n is zero or an integer of one to eight and R47 and R48 are independently hydrogen, fluorine, chlorine, bromine, hydroxy, alkyl of from one to three carbon atoms, or alkoxy of from one to three carbon atoms, or alkoxy of from one to four carbon atoms, or
Figure imgf000098_0002
wherein
R47 and R48 are as defined above;
X is oxygen or sulfur;
R44 is alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms alkenyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or
Figure imgf000099_0001
wherein n, R47 and R48 are as defined above R45 and R46 are each independently hydrogen, alkyl of from one to twenty carbon atoms, alkyl of from one to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to twenty carbon atoms, alkenyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to twenty carbon atoms, alkynyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to eight carbon atoms, phenyl, phenyl substituted with alkyl of from one to four carbon atoms, alkyl of from one to four carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkoxy of from one to four carbon atoms, chlorine, bromine, hydroxy, nitro or trifluoromethyl of R45 and R46 are taken together with the nitrogen atom to which they are attached to form
Figure imgf000099_0002
wherein R49 is hydrogen, alkyl of from one to ten carbon atoms, alkyl of from one to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to ten carbon atoms, alkenyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms and n is as defined above,
Figure imgf000100_0001
wherein X is defined above or
Figure imgf000100_0002
wherein R50 is hydrogen or alkyl of from one to six carbon atoms,
Figure imgf000100_0003
wherein R51 is selected from the group consisting of
Figure imgf000101_0001
R52 is hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms or aryl; n' is zero or an integer of one or two; X' is carbon or nitrogen; and ... represents a single or double bond with the proviso that when, __^_L_ represents a double bond X' is nitrogen and when j.^ represents a single bond X' is CH2; 53
Figure imgf000102_0001
wherein R53 is selected from the group consisting
Figure imgf000102_0002
R54, R55, R56, and R57 are each independenty hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms, phenyl or phenyl substituted by one to four substituents selected from C1-C10 alkyl, alkoxy, C1-C10 halogen or trifluoromethyl; n' is an interger of one or two;
Figure imgf000102_0003
wherein X is oxygen, sulfur, or -N-R62, wherein R62 is hydrogen or alkyl of from one to ten carbon atoms; R 8 is selected from the group consisting of
Figure imgf000103_0001
R59, R60, and R61 are each independently hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms or aryl; represents a single or double bond with the proviso that when represents a double bond R57 and R60 are absent;
Figure imgf000104_0001
wherein R63, R64, and R65 are each independently hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms, phenyl or phenyl substituted by one to four substituents selected from the group consisting of alkyl, alkoxy, thioalkoxy, halogen, and trifluoromethyl; R66 is hydrogen, hydroxy or alkoxy of from one to ten carbon atoms; and R67 is selected from the group consisting of
Figure imgf000104_0002
Figure imgf000104_0003
Figure imgf000104_0004
Figure imgf000105_0001
wherein
R69 is hydrogen and R67 is hydrogen, alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms, alkenyl of from three to six carbon atoms, substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or
R68 and R69 are taken together with the nitrogen atom to which they are attached to form a ring denoted by
Figure imgf000105_0002
wherein n' is zero or an integer from one to eight and R73 is hydrogen, alkyl of from one to ten carbon atoms, alkyl of from one to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to ten carbon atoms, alkenyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to ten carbon atoms or alkynyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms; R70 is hydrogen, alkyl of from one to six carbon atoms, alkyl of form one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms, alkenyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or R70 when taken together with R68 forms a ring denoted by
Figure imgf000106_0001
n
wherein n is an integer from one to three and R68 are as defined above;
R71 and R72 are each independently hydrogen, alkyl of from one to twenty carbon atoms, alkyl of from one to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to twenty carbon atoms, alkenyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to twenty carbon atoms, alkynyl of from three to twenty carbon atoms substituted with dydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to eight carbon atoms, phenyl, phenyl substituted with alkyl of from one to four carbon atoms, alkyl of from one to four carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkoxy of from one to four carbon atoms, chlorine, bromine, hydroxy, nitro or trifluoromethyl of R3 and R4 are taken together with the nitrogen atom to which they are attached to form
wherein n' and R73 are as defined above,
Figure imgf000107_0002
wherein X is defined above or
Figure imgf000107_0003
wherein R74 is hydrogen or alkyl of from one to six carbon atoms,
Figure imgf000107_0004
in which Z is a heterocyclic group
Figure imgf000108_0001
in which Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, or three nitrogen atoms, any amino nitrogen being substituted by a Cι-2 alkyl, cyclopropyl or propargyl group, and any ring carbon atom being optionally substituted by a group Ri; or a group
Figure imgf000108_0002
in which Ai, A2 and A3 complete a 5-membered aromatic ring and Ai is oxygen or sulphur, one of A2 and A3 is CR2 and the other is nitrogen or CR3, or A2 is oxygen or sulphur, one of Ai and A3 is CR2 and the other is CR3; and Ri, R2 and R3 are independently selected from hydrogen, halogen, CN, OR4, SR4, N(R4)2, NHCOR4, NHCOOCH3, NHCOOC2H5, NHOR4, NHNH2, N0 , COR4, COR5, cyclopropyl, C2-5 straight chain alkenyl, C2-5 straight chain alkynyl or C1-5 straight chain alkyl optionally terminally substituted with OR , N(R4)2# SR4, CO2R4, CON(R4)2 or one, two or three halogen atoms, in which each R4 is independently hydrogen or C1-3 alkyl and R5 is OR4, H2 or NHR ; or in which Z is a group -C(R7)=NRς in which Rβ is a group OR8, where R8 is C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, a group OCOR9 where R9 is hydrogen or R8, or a group NHR10 or NR11R12 where Rio, Rli and R12 are independently C]_- 2 alkyl and R7 is hydrogen or C3.-4 alkyl, subject to the proviso that when Rζ is a group OCOR9 or NHR10 - 7 is C1- 4 alkyl ;
Figure imgf000109_0001
in which one of X and Y represents hydrogen and the other represents Z, and Z' is a group
Figure imgf000109_0002
in which Q1 represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises two or three nitrogen atoms, any amino nitrogen being substituted by a Cl-2 alkyl, cyclopropyl or propargyl group, r represents the integer of 2 or 3 , s represents an integer of 1 or 2 and t represents 0, with the proviso that when Y is hydrogen s is 1;
Figure imgf000109_0003
wherein R75 represents
Figure imgf000110_0001
in which each of p and q independently represents an integer of 2 to 4, r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;
R76 is a group OR78, where R78 is C3.-4 alkenyl, C2-4 alkynyl, a group OCOR79 where R79 is hydrogen or R78, or a group NHR80 or NR81, R82, where R80, R81 and R82 are independently C1-2 alkyl; and R77 is hydrogen or C _4alkyl, subject to the proviso that when R76 is a group OCOR79 or a group NHR80, R77 is alkyl;
(3R,4R) -3- (3-cyclopropyl-1,2,4-oxadiazol-5-yl) -1- a abicyclo[2.2.lheptane; or a pharmaceutically acceptable salt or solvate thereof; and one or more Synergistic Analgesics in a weight ratio of
Compound to Synergistic Analgesic of from about 1 to about
1000.
23. A method as claimed by Claim 22 wherein the Compound is selected from the group consisting of Formula IV, V, VIII, IX, XIII, XIV, and XV; or a pharmaceutically acceptable salt or solvate thereof. 24. A method as claimed by Claim 22 wherein the Synergistic Analgesic is a nonsteroidal anti-inflammatory drug.
25. A method as claimed by Claim 24 wherein the nonsteroidal anti-inflammatory drug is selected from the group consisting of indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac.
26. A method as claimed by Claim 24 wherein the nonsteroidal anti-inflammatory drug is ibuprofen.
27. A method as claimed by Claim 24 wherein the Compound is selected from the group consisting of Formula IV,
V, VIII, IX, XIII, XIV, and XV; or a pharmaceutically acceptable salt or solvate thereof.
28. A method as claimed by Claim 22 wherein the Synergistic Analgesic is an opioid.
29. A method as claimed by Claim 28 wherein the Compound is selected from the group consisting of Formula IV, V, VIII, IX, XIII, XIV, and XV; or a pharmaceutically acceptable salt or solvate thereof.
30. A method as claimed by Claim 29 wherein the Compound is selected from the group consisting of l-azabicyclo[2.2.2]oct-3-yl cyclopropyl ketone, 1-azabicyclo[2.2.l]hept-3-yl cyclopropyl ketone,
3-oxo-3- (1-azabicyclo[2.2.1]hept-3-yl)propionitrile, 1-azabicyclo[2.2.2]oct-3-yl-N-methoxycarboxamide, 1-azabicyclo[3.2.1]oct-5-yl-N-methoxycarboxamide, 1-azabicyclo[2.2.l]hept-3-yl-N-methoxycarboxamide, (methoxyimino) - (1-azabicyclo [2.2.2] oct-3-yl) acetonitrile, oximino- (1-azabicyclo[2.2.2]oct-3-yl) acetonitrile, and 1-azabicyclo [2.2.2]oct-3-ylidecyanoacetic acid; or a pharmaceutically acceptable salt thereof.
31. A method as claimed by Claim 29 wherein the opioid is selected from the group consisting of morphine, codeine, meperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, brompton's cocktail, naloxone, naltrexone, pentazocine, butorphanol, nabuphine, and buprenorphine.
32. A method as claimed by Claim 29 wherein the opioid is selected from the group consisting of hydromorphone, hydrocodone, meperidone, buprenorphine, butorphenol, nalbuphine, pentazocine, oxymorphine, oxycodone, levorphanol, fentanyl, and alphaprodine.
33. A method as claimed by Claim 29 wherein the opioid is selected from the group consisting of propoxyphene, methadone, hydrocodone, hydromorphine, and codeine.
34. A method as claimed by Claim 22 wherein the
Compound is selected from the group consisting of Formula I, II, and III; or a pharmaceutically acceptable salt or solvate thereof.
35. A method as claimed by Claim 22 wherein the Compound is selected from the group consisting of Formula XIV and XV; or a pharmaceutically acceptable salt or solvate thereof.
36. A method as claimed by Claim 35 wherein the Compound is selected from the group consisting of l-azabicyclo[2.2.2]oct-3-yl cyclopropyl ketone, l-azabicyclo[2.2.l]hept-3-yl cyclopropyl ketone, 3-oxo-3- (1-azabicyclo[2.2.1]hept-3-yl)propionitrile, 1-azabicyclo[2.2.2]oct-3-yl-N-methoxycarboxamide, 1-azabicyclo[3.2.1]oct-5-yl-N-methoxycarboxamide, l-azabicyclo[2.2.1]hept-3-yl-N-methoxycarboxamide, (methoxyimino) - (1-azabicyclo[2.2.2] oct-3-yl)acetonitrile, oximino- (1-azabicyclo[2.2.2]oct-3-yl)acetonitrile, and l-azabicyclo[2.2.2]oct-3-ylidecyanoacetic acid; or a pharmaceutically acceptable salt thereof.
37. A method as claimed by Claim 22 wherein the
Synergistic Analgesic is acetaminophen.
38. A method as claimed by Claim 37 wherein the Compound is selected from the group consisting of Formula IV, V, VIII, IX, XIII, XIV, and XV; or a pharmaceutically acceptable salt or solvate thereof.
39. A method as claimed by Claim 22 wherein the Synergistic Analgesic is an alpha-adrenergic compound.
40. A method as claimed by Claim 39 wherein the Compound is selected from the group consisting of Formula IV, V, VIII, IX, XIII, XIV, and XV; or a pharmaceutically acceptable salt or solvate thereof.
41. A method as claimed by Claim 40 wherein the Compound is selected from the group consisting of 1-azabicyclo[2.2.2] oct-3-yl cyclopropyl ketone, l-azabicyclo[2.2.l]hept-3-yl cyclopropyl ketone, 3-oxo-3- (1-azabicyclo[2.2.1]hept-3-yl)propionitrile, l-azabicyclo[2.2.2]oct-3-yl-N-methoxycarboxamide, 1-azabicyclo[3.2.lJoct-5-yl-N-methoxycarboxamide, 1-azabicyclo[2.2.1]hept-3-yl-N-methoxycarboxamide, (methoxyimino) - (1-azabicyclo[2.2.2] oct-3-yl)acetonitrile, oximino- (1-azabicyclo[2.2.2]oct-3-yl)acetonitrile, and l-azabicyclo[2.2.2]oct-3-ylidecyanoacetic acid; or a pharmaceutically acceptable salt thereof.
42. The use of a First Compound selected from the group consisting of
Figure imgf000114_0001
wherein R1 is hydrogen, Ci-Cβ alkyl or phenyl-Cι~C4 alkyl, in which the phenyl group may be substituted with halogen, C1-C4 alkyl or C1-C4 alkoxy;
R2 is Ci-Cβalkyl, C3-C6 alkenyl, C3-C6 alkynyl, branched or unbranched with 1-6 carbon atoms inclusive, which group may be optionally substituted with fluoro, hydroxy or phenyl optionally substituted with fluoro, trifluoromethyl, lower alkyl, hydroxy, or lower alkoxy;
R3 and R4 are independently hydrogen, Cι~Cs alkyl, C3-C6 cycloalkyl, phenyl optionally substituted with halogen trifluroromethyl, C -C4 alkyl, hydroxy, or C1-C4 alkoxy, or phenyl-C1-C4 alkyl, in which the phenyl group may be substituted with halogen, C1-C4 alkyl or C1-C4 alkoxy;
Figure imgf000114_0002
in which R5 represents the radical
Figure imgf000114_0003
in which R6 at any position on the benzene ring represents linear, branched or cyclic Ci~Cs alkyl, C2-C8 alkenyl or C2- Cδ alkynyl or the radical R7
in which R7 and R8 which may be identical or different represent hydrogen, linear Ci-Cβ alkyl, C2-C8 alkenyl or C2- Cβ alkynyl or form together with the nitrogen atom to which they are attached a carbonaceous hetercyclic radical optionally containing another heteroatom, or the radical OR9, R9 representing hydrogen, linear, branched or cyclic Ci-Cβ alkyl, C2-C8 alkenyl or C2-C8 alkynyl or aryl containing up to 14 carbon atoms, or the radical SR10 or S(0)Rn, R10 and R11 represent linear, branched or cyclic Ci-Cβ alkyl, C2-C8 alkenyl or C2-C8 alkynyl, or R5 represents naphthyl optionally substituted with R6' - R6' being defined above for R6;
Figure imgf000115_0001
in which R12 represents the radical
Figure imgf000115_0002
in which R13 at any position on the benzene ring represents linear, branched or cyclic C -CQ alkyl, C2-C8 alkenyl or C2- C8 alkynyl or the radical
,14
N~R'=
in which R14 and R15 which may be identical or different represent hydrogen, linear Ci-Cs alkyl, C2-C8 alkenyl or C2- Cβ alkynyl or form together with the nitrogen atom to which t ey are attached a carbonaceous hetercyclic radical optionally containing another heteroatom, or the radical or NO2, or OR12', R12' representing hydrogen, linear, branched or cyclic Ci-Cg alkyl, C2-C8 alkenyl or C2-C8 alkynyl or aryl containing up to 14 carbon atoms, or the radical SR16 or S(0)R17, R16 and R17 represent linear, branched or cyclic Cι~ Cβ alkyl, C2-C8 alkenyl or C2-C8 alkynyl, or R12 represents naphthyl optionally substituted with R13 ' - R13 ' being defined above for R13;
Figure imgf000116_0001
wherein, one of R18, R19, and R20 represents nitrogen and the remainder represent carbon atoms; substituted on one of the ring carbon atoms with a R24 substituent represented by a non¬ aromatic azacyclic or azabicyclic ring system and independently substituted on each of the other ring carbon atoms with R23, R21, or R22 substituent of low lipophilicity or a hydrocarbon having a maximum of 20 carbon atoms;
Figure imgf000116_0002
wherein one of R28, R29 or R30 is an oxygen atom and the other two are nitrogen atoms, and the dotted circle represents aromaticity (two double bonds) thus forming a
1,3, 4-oxadiazole or 1, 2, -oxadiazole nucleus; R31 represents a non-aromatic '927azacycle or ' 927azabicyclic ring system; and R32 represents a substituent which is convertable in vivo to an amino group;
Figure imgf000117_0001
wherein R34 represents a non-aromatic; non-fused 1- azabicyclic ring system; and
R35, R36, and R37 independently represent hydrogen, F, Cl, Br, -CF3, -OR38, -NR38R39, -NHOR38, -NHNH , -CN, COR40, or a substituted or unsubstituted, saturated or unsaturated hydrocarbon group, provided that at least one of R35, R36, and R37 is other than hydrogen or a hydrocarbon group, or R35 and R36 or R37 taken together form a Ci-βalkylenedioxy ring, wherein R38 is Cι_6alkyl, C2-6alkenyl or C2-6alkynyl, R39 is hydrogen, Cι_6 alkyl,or -COCH3, and R40 represents OH, -OR38, NHR39, or -NR38R39
Figure imgf000117_0002
wherein R43 is alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to six carbon atoms, alkenyl of from two to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to six carbon atoms, alkynyl of from two to six carbon atoms, substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms,
Figure imgf000118_0001
wherein n is zero or an integer of one to eight and R47 and R48 are independently hydrogen, fluorine, chlorine, bromine, hydroxy, alkyl of from one to three carbon atoms, or alkoxy of from one to three carbon atoms, or alkoxy of from one to four carbon atoms, or
Figure imgf000118_0002
wherein
R47 and R48 are as defined above;
X is oxygen or sulfur;
R44 is alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms alkenyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or
Figure imgf000119_0001
wherein n, R47 and R48 are as defined above R45 and R46 are each independently hydrogen, alkyl of from one to twenty carbon atoms, alkyl of from one to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to twenty carbon atoms, alkenyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to twenty carbon atoms, alkynyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to eight carbon atoms, phenyl, phenyl substituted with alkyl of from one to four carbon atoms, alkyl of from one to four carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkoxy of from one to four carbon atoms, chlorine, bromine, hydroxy, nitro or trifluoromethyl of R45 and R46 are taken together with the nitrogen atom to which they are attached to form
Figure imgf000119_0002
wherein R49 is hydrogen, alkyl of from one to ten carbon atoms, alkyl of from one to ten carbon atoms substituted with -llβ- hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to ten carbon atoms, alkenyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms and n is as defined above,
Figure imgf000120_0001
wherein X is defined above or
Figure imgf000120_0002
wherein R50 is hydrogen or alkyl of from one to six carbon atoms,
Figure imgf000120_0003
wherein R51 is selected from the group consisting of
Figure imgf000121_0001
R52 is hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms or aryl; n' is zero or an integer of one or two; X' is carbon or nitrogen; and ^_JJt_represents a single or double bond with the proviso that when, _,_,_,_ represents a double bond X' is nitrogen and when _J_J___ represents a single bond X' is CH2;
Figure imgf000122_0001
wherein R53 is selected from the group consisting
Figure imgf000122_0002
R54, R55, R56, and R57 are each independenty hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms, phenyl or phenyl substituted by one to four substituents selected from C1-C10 alkyl, alkoxy, C1-C10 halogen or trifluoromethyl; n' is an interger of one or two;
Figure imgf000122_0003
wherein X is oxygen, sulfur, or -N-R62, wherein R62 is hydrogen or alkyl of from one to ten carbon atoms; R58 is selected from the group consisting of
Figure imgf000123_0001
R59, R60, and R61 are each independently hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms or aryl; represents a single or double bond with the proviso that when represents a double bond R57 and R60 are absent;
Figure imgf000124_0001
wherein R63, R64, and R65 are each independently hydrogen, alkyl of from one to ten carbon atoms, alkynyl of from two to ten carbon atoms, phenyl or phenyl substituted by one to four substituents selected from the group consisting of alkyl, alkoxy, thioalkoxy, halogen, and trifluoromethyl; R66 is hydrogen, hydroxy or alkoxy of from one to ten carbon atoms; and R67 is selected from the group consisting of
Figure imgf000124_0002
Figure imgf000124_0003
Figure imgf000124_0004
Figure imgf000125_0001
wherein
R69 is hydrogen and R67 is hydrogen, alkyl of from one to six carbon atoms, alkyl of from one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms, alkenyl of from three to six carbon atoms, substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or
R68 and R69 are taken together with the nitrogen atom to which they are attached to form a ring denoted by
Figure imgf000125_0002
wherein n' is zero or an integer from one to eight and R73 is hydrogen, alkyl of from one to ten carbon atoms, alkyl of from one to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from two to ten carbon atoms, alkenyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from two to ten carbon atoms or alkynyl of from two to ten carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms; R70 is hydrogen. alkyl of from one to six carbon atoms, alkyl of form one to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to six carbon atoms, alkenyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to six carbon atoms, alkynyl of from three to six carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to six carbon atoms, or R70 when taken together with R68 forms a ring denoted by
Figure imgf000126_0001
n
wherein n is an integer from one to three and R68 are as defined above;
R71 and R72 are each independently hydrogen, alkyl of from one to twenty carbon atoms, alkyl of from one to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkenyl of from three to twenty carbon atoms, alkenyl of from three to twenty carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkynyl of from three to twenty carbon atoms, alkynyl of from three to twenty carbon atoms substituted with dydroxy or alkoxy of from one to four carbon atoms, cycloalkyl of from three to eight carbon atoms, phenyl, phenyl substituted with alkyl of from one to four carbon atoms, alkyl of from one to four carbon atoms substituted with hydroxy or alkoxy of from one to four carbon atoms, alkoxy of from one to four carbon atoms, chlorine, bromine, hydroxy, nitro or trifluoromethyl of R3 and R4 are taken together with the nitrogen atom to which they are attached to form a ring denoted by
Figure imgf000127_0001
wherein n' and R73 are ad defined above,
Figure imgf000127_0002
wherein X is defined above or
Figure imgf000127_0003
wherein R74 is hydrogen or alkyl of from one to six carbon atoms,
Figure imgf000127_0004
in which Z is a heterocyclic group
Figure imgf000128_0001
in which Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, or three nitrogen atoms, any amino nitrogen being substituted by a Cι_2 alkyl, cyclopropyl or propargyl group, and any ring carbon atom being optionally substituted by a group Ri; or a group
Figure imgf000128_0002
in which Ai, A2 and A3 complete a 5-membered aromatic ring and Ai is oxygen or sulphur, one of A2 and A3 is CR2 and the other is nitrogen or CR3, or A2 is oxygen or sulphur, one of Ai and A3 is CR2 and the other is CR3; and Ri, R2 and R3 are independently selected from hydrogen, halogen, CN, OR4, SR4, N(R4) , NHCOR4, NHCOOCH3, NHCOOC2H5, NHOR4, NHNH , N02, COR4, COR5, cyclopropyl, C2-5 straight chain alkenyl, C2-5 straight chain alkynyl or C1-5 straight chain alkyl optionally terminally substituted with OR4, N(R4>2, SR4, CO2R4, CON(R4)2 or one, two or three halogen atoms, in which each R4 is independently hydrogen or C1-3 alkyl and R5 is OR4, NH2 or NH.R4; or in which Z is a group -C(R7)=NR6 in which Rβ is a group OR8, where R8 is Cι_4 alkyl, C2-4 alkenyl, C2-4 alkynyl, a group OCOR9 where R9 is hydrogen or R8, or a group NHR10 or R11R12 where Rχo, Rll and R12 are independently Cχ_ 2 alkyl and R7 is hydrogen or Ci-4 alkyl, subject to the proviso that when Rg is a group OCORg or NHRio, R7 is C1-4 alkyl
Figure imgf000129_0001
in which one of X and Y represents hydrogen and the other represents Z, and Z' is a group
Figure imgf000129_0002
in which Q* represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises two or three nitrogen atoms, any amino nitrogen being substituted by a Cl-2 alkyl, cyclopropyl or propargyl group, r represents the integer of 2 or 3, s represents an integer of 1 or 2 and t represents 0, with the proviso that when Y is hydrogen ε is 1;
Figure imgf000129_0003
wherein R75 represents
Figure imgf000130_0001
in which each of p and q independently represents an integer of 2 to 4, r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;
R76 is a group OR78, where R78 is C1-4 alkenyl, C2-4 alkynyl, a group OCOR79 where R79 is hydrogen or R78, or a group NHR80 or NR81, R82, where R80, R81 and R82 are independently C1-2 alkyl; and R77 is hydrogen or Cι_4alkyl, subject to the proviso that when R76 is a group OCOR79 or a group NHR80, R77 is alkyl;
(3R,4R)-3- (3-cyclopropyl-1,2,4-oxadiazol-5-yl)-1- azabicyclo[2.2.lheptane; or a pharmaceutically acceptable salt or solvate thereof; and one or more Synergistic Analgesics in a weight ratio of
First Compound to Synergistic Analgesic of from about 1 to about 1000 for a manufacture of a medicament for therapeutic application in the treatment of pain.
43. A use as claimed by Claim 42 wherein the
Synergistic Analgesic is an opioid.
44. A use as claimed by Claim 42 wherein the Synergistic Analgesic is acetaminophen. 45. A use as claimed by Claim 42 wherein the Synergistic Analgesic is a nonsteroidal anti-inflammatory drug.
46. A use as claimed by Claim 42 wherein the Synergistic Analgesic is an alpha-adrenergic compound.
PCT/US1996/019309 1995-12-07 1996-12-05 Composition for treating pain WO1997020561A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
HU9902118A HUP9902118A2 (en) 1996-12-05 1996-12-05 Synergistic pharmaceutical composition for treating pain
EA199800533A EA199800533A1 (en) 1995-12-07 1996-12-05 COMPOSITION FOR THE TREATMENT OF PAIN
IL12441996A IL124419A0 (en) 1995-12-07 1996-12-05 Composition for treating pain
AU12791/97A AU705031B2 (en) 1995-12-07 1996-12-05 Composition for treating pain
NZ324988A NZ324988A (en) 1995-12-07 1996-12-05 Composition for treating pain comprising a selected muscarinic compound and an analgesic or nsaid
KR1019980704267A KR19990071976A (en) 1995-12-07 1996-12-05 Pain Treatment Composition
PL96327137A PL327137A1 (en) 1995-12-07 1996-12-05 Pain relieving agent
JP9521397A JP2000501709A (en) 1995-12-07 1996-12-05 Composition for treating pain
EP96943584A EP0871445A4 (en) 1995-12-07 1996-12-05 Composition for treating pain
NO982562A NO982562L (en) 1995-12-07 1998-06-04 Composition for the treatment of pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US829995P 1995-12-07 1995-12-07
US60/008,299 1995-12-07

Publications (1)

Publication Number Publication Date
WO1997020561A1 true WO1997020561A1 (en) 1997-06-12

Family

ID=21730869

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/019309 WO1997020561A1 (en) 1995-12-07 1996-12-05 Composition for treating pain

Country Status (13)

Country Link
EP (1) EP0871445A4 (en)
JP (1) JP2000501709A (en)
KR (1) KR19990071976A (en)
CN (1) CN1208349A (en)
AU (1) AU705031B2 (en)
CA (1) CA2238815A1 (en)
CZ (1) CZ174698A3 (en)
EA (1) EA199800533A1 (en)
IL (1) IL124419A0 (en)
NO (1) NO982562L (en)
NZ (1) NZ324988A (en)
PL (1) PL327137A1 (en)
WO (1) WO1997020561A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1007041A1 (en) * 1997-04-11 2000-06-14 Eli Lilly And Company Composition for treating pain
US6559171B1 (en) 1999-06-04 2003-05-06 Eli Lilly And Company 7-oxo-2-azabicyclo[2.2.1]heptanes as selective muscarinic receptor antagonist
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10959958B2 (en) 2014-10-20 2021-03-30 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2998450A (en) * 1958-05-19 1961-08-29 Warner Lambert Pharmaceutical Process of preparing nu-acetyl-p-amino phenol
US4923880A (en) * 1988-03-14 1990-05-08 H. Lundbeck A/S 4,5,6,7-Tetrahydroisothiazolo (4,5-c) pyridine derivatives
US5242927A (en) * 1987-07-23 1993-09-07 Merck Sharp & Dohme Limited Prodrugs for oxadiazole muscarinic agonists
US5260293A (en) * 1988-01-30 1993-11-09 Merck Sharp & Dohme Limited Pyrazines, pyrimidines and pyridazines useful in the treatment of senile dementia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
US5418240A (en) * 1990-08-21 1995-05-23 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
EP0785779A1 (en) * 1994-03-18 1997-07-30 Bayer Corporation Low dosage ketoprofen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2998450A (en) * 1958-05-19 1961-08-29 Warner Lambert Pharmaceutical Process of preparing nu-acetyl-p-amino phenol
US5242927A (en) * 1987-07-23 1993-09-07 Merck Sharp & Dohme Limited Prodrugs for oxadiazole muscarinic agonists
US5260293A (en) * 1988-01-30 1993-11-09 Merck Sharp & Dohme Limited Pyrazines, pyrimidines and pyridazines useful in the treatment of senile dementia
US4923880A (en) * 1988-03-14 1990-05-08 H. Lundbeck A/S 4,5,6,7-Tetrahydroisothiazolo (4,5-c) pyridine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0871445A4 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1007041A1 (en) * 1997-04-11 2000-06-14 Eli Lilly And Company Composition for treating pain
EP1007041A4 (en) * 1997-04-11 2001-03-07 Lilly Co Eli Composition for treating pain
US6559171B1 (en) 1999-06-04 2003-05-06 Eli Lilly And Company 7-oxo-2-azabicyclo[2.2.1]heptanes as selective muscarinic receptor antagonist
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10639281B2 (en) 2013-08-12 2020-05-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10792254B2 (en) 2013-12-17 2020-10-06 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10959958B2 (en) 2014-10-20 2021-03-30 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form

Also Published As

Publication number Publication date
AU705031B2 (en) 1999-05-13
NO982562L (en) 1998-07-10
CA2238815A1 (en) 1997-06-12
EP0871445A4 (en) 2001-01-10
NO982562D0 (en) 1998-06-04
PL327137A1 (en) 1998-11-23
KR19990071976A (en) 1999-09-27
NZ324988A (en) 1999-08-30
IL124419A0 (en) 1998-12-06
EA199800533A1 (en) 1999-02-25
CZ174698A3 (en) 1998-10-14
JP2000501709A (en) 2000-02-15
EP0871445A1 (en) 1998-10-21
AU1279197A (en) 1997-06-27
CN1208349A (en) 1999-02-17

Similar Documents

Publication Publication Date Title
US5998434A (en) Composition for treating pain
KR101302898B1 (en) Combinations of nicotinic acetylcholine alpha 7 receptor agonists
SK13952002A3 (en) A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
JP6419294B2 (en) Methods of using cyclic amide derivatives to treat sigma receptor mediated disorders
MX2007011436A (en) Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions.
US20090197823A1 (en) Aliskiren modulation of neurogenesis
WO2002036113A1 (en) Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
EP0871445A1 (en) Composition for treating pain
WO2002036114A1 (en) Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3
AU715645B2 (en) Method for treating pain
WO1997020556A9 (en) Method for treating pain
MXPA06011772A (en) Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative.
EP3265128A1 (en) Oxybutynin transdermal therapeutic system muscarinic agonist combination
WO2001095902A9 (en) A composition comprising a combination of receptor agonists and antagonists
WO2001095902A1 (en) A composition comprising a combination of receptor agonists and antagonists
RU2419433C2 (en) Mediciation for prevention and treatment of alcohol dependence and dependence from medications
WO1998046227A1 (en) Composition for treating pain
WO1998046601A1 (en) Composition for treating pain
EP0783304A1 (en) Method for treating anxiety
MXPA98004519A (en) Composition to treat do
Toma et al. Neuronal nicotinic acetylcholine receptor agonists
Theberge et al. Drugs Affecting the Cholinergic System
MXPA98004525A (en) Method for treating do

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96199837.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 324988

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2238815

Country of ref document: CA

Ref document number: 2238815

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996943584

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/004519

Country of ref document: MX

Ref document number: PV1998-1746

Country of ref document: CZ

Ref document number: 1019980704267

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1997 521397

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 199800533

Country of ref document: EA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1998-1746

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1996943584

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980704267

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1998-1746

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1996943584

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019980704267

Country of ref document: KR